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Lipopolysaccharide (LPS, also known as endotoxin) present on the outer 
membrane of the Gram negative bacteria , causes septic shock when introduced 
intravenously.   It is generally thought that LPS interacts with LPS-effectors on the 
host cell membrane to activate the intracellular  signaling pathway resulting in host 
inflammation and ultimately, septic shock.  Thus, developing biomolecules which 
are capable of binding LPS at high affinity is an efficient way to neutralize the 
endotoxicity and confer antimicrobial effects.  Currently, many LPS-neutralizing 
peptides have been derived from LPS-binding proteins. Efforts are also underway to 
increase their  impotency and specificity for LPS so that they are only toxic to 
microbes and not to mammalian hosts. Factor C, a serine protease in the horseshoe 
crab hemocytes, is sensitive to trace levels of LPS.  Our work demonstrated that 
Factor C efficiently inhibited the LPS-induced p38 phosphorylation and cytokine 
production, indicating its anti-LPS potentials. Thus, in this work, the efficacy of the 
small LPS-binding peptides derived from Factor C (Sushi peptides , S1 and S3) was 
tested.  Although earlier studies have shown that S1 & S3 were able to bind LPS, the 
molecular mechanisms of the interaction between the Sushi peptides and LPS remain 
unclear.  Towards this, multimer cassettes of recombinant S3 (rS3) peptide was 
expressed, purified and digested into monomeric  rS3 peptides for LPS-neutralizing  
assays.  However the rS3 was found to be less active than the chemically synthesized 
S3 peptide. Therefore, we focused our investigation on the mechanism of the 
 vii 
interaction between chemically synthesized Sushi peptides (S1 & S3)  and LPS. The 
investigation of the structure-activity relationship of the Sushi peptides employed a 
series of biophysical methods, including circular dichroism (CD), surface plasmon 
resonance (SPR) and fluorescence correlation spectroscopy (FCS).  Using FCS, we 
describe a novel approach to examine the mechanism of peptide interaction with LPS 
in solution phase.  It was evident that S1 is functional in its monomeric form while 
S3 is more active in a dimeric form.  Both of the Sushi peptides display 
detergent -like properties in disrupting LPS aggregates.  The specificity of the Sushi 
peptides for  POPG (palmitoyl-oleoyl-phosphatidylglycerol), anionic phospholipids  
co-existed on bacterial membrane with LPS, appears to be a consequence of 
electrostatic and hydrophobic forces.  The unsaturated nature of the lipid molecules  
confers fluidity to the lipid layer and probably enhances the binding and insertion of 
the peptide into the lipid layer.  It was observed that during its interaction with POPG, 
the S1 peptide transitioned from random coil to a-helix.  Unlike S1, the S3 peptide  
remained virtually unchanged in solution, only with slight increase in the content  of 
a-helix when in the presence of LPS-analogue, giving a mixture of a-helix and 
ß-sheet structures.  Thus, the hypothetical models of the interaction between the 
Sushi peptides and LPS were proposed.  Conceivably, the molecular mechanism of 
this interaction could be helpful to design and develop a new generation of 
LPS-neutralizing drug and also to offer some clues on the specific function of Factor 
C, an LPS-biosensor.  
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1.1 Gram negative septicaemia 
Infection by Gram negative bacteria is the leading cause of sepsis (Bone, 1996; 
McCormick et al., 2001). Bacterial infections can originate from exogenous and 
endogenous sources (Lemaire et al., 1997; Lent et al., 2001; Van Leeuwen et al., 
1994).  Septicaemia is a serious medical problem which results in high mortality.   
The term sepsis is used when an acute activation of the inflammatory network is 
induced via  infection by bacteria, fungus , virus or parasite in host blood (McCormick 
et al., 2001).  The clinical pattern of this acute inflammation is called systemic 
inflammatory response syndrome (SIRS).  Symptoms of septic shock include 
deranged haemodynamics, circulatory failure, leukocyte -induced tissue injury, 
coagulatory disorders and fever  (Table 1) (Karima et al., 1999). Pyrogens are 
substances that can cause fever when introduced intravenously.  The best studied 
biological pyrogen is lipopolysaccharide (LPS, endotoxin) found in the outer 
membrane of Gram negative bacteria (GNB) (Figure 1.1A ). Despite extensive 
research on Gram negative septicaemia and effor ts to develop antibiotics, infection by 
GNB is still a leading cause of sepsis, accounting for 45 – 60 % of sepsis caused by 
bacterial infection (Bone, 1996; McCormick et al., 2001).  In sepsis due to Gram 
negative bacteria, LPS stimulates host macrophages to release inflammatory 
cytokines, causing inflammation which informs the host of pathogen invasion.  
However, excessive inflammation causes septic shock. Subsequently, multiple organ 
failure ensues and becomes the main clinical problem and cause of mortality (Brady 
and Otto, 2001). Persistence of endotoxin exposure triggers the inflammatory 
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response out of control, resulting in septic shock that can rapidly kills the patient 
before the bacteria could cause any direct harm (Ruiter et al., 1981). In the United 
States, a multicentre observational cohort study ha s projected an estimated 751,000 
cases of sepsis per annum (Angus and Wax, 2001).   In Singapore, septicaemia is 
the 10th principal cause of death, with about 100 people dying from it each year  
(Ministry of Health, 2005) . 
 Besides LPS, GNB releases other PAMPs (pathogen-associated molecular 
patterns), such as CpG-DNA, triacyl lipopeptides and other unidentif ied substances, 
which also induce the secretion of cytokines. In addition, a mixture of pyrogens are 






Table 1 Clinical features of organ dysfunction in sepsis 
Organ/system  Symptom 
Central nervous system 
(CNS) 
Reduced alertness, confusion, stupor or coma; drifting in and 
out of consciousness. 
Cardiovascular system Decrease in bilateral ventricular contractility, although 
cardiac output can be increased to supranormal levels. 
Decrease in systemic vascular resistance. 
Lung Hypoxemia that frequently necessitates support with 
mechanical ventilation with PEEP. 
Widespread, patchy or homogeneous bilateral infiltrates in 
chest X-ray, although radiographic abnormalities are often 
absent within a few days of onset.  
Decrease in pulmonary compliance and increased airway 
resistance. 
Liver Progressive increase in plasma bilirubin levels with moderate 
increase in plasma transaminase levels.  
Reduced amino acid extraction with reduced protein 
synthesis. 
Increased hepatic VLDL release with reduced peripheral 
triglyceride clearance. 
Impaired glucose release that often results in hypoglycemia . 
Kidney Increase in plasma levels of BUN and creatinine with reduced 
GFR. 
Oliguria or anuria, although sometimes urinary volume is 
maintained within normal or polyuremic limits. 
Coagulation system Decrease in plasma fibrinogen and antithrombin III levels. 
Increase in FDP and prolongation of clotting time. 
 
BUN, blood urea nitrogen; FDP, fibrinogen degradation products; GFR, glomerular filtration 
rate; PEEP, positive end-expiratory pressure; VLDL, very low density lipoprotein. Adapted 
from Kamira et al. (1999). (Karima et al., 1999) 
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1.2 Structural features of LPS  
Studies on the molecular biology of Gram negative septicaemia  have so far 
focused on the chemical structure of LPS, which is anchored on the outer cell wall of 
GNB (Brandenburg and Wiese, 2004).  LPS are also referred to as endotoxin 
because of their toxic and pyrogenic (fever causing) properties in human and other 
mammalian hosts.  This term was introduced in the 19th century to describe a 
component of GNB responsible for the pathophysiological phenomena associated 
with GNB.  Endotoxins are resilient, indomitable and ubiquitous molecule s.  They 
are uniquely thermostable and fairly insensitive to pH changes.  Removing 
endotoxin requires a high heat of 200 oC for at least two hours, or short durations in 
high concentrations of acids or bases, for example in citric acid, pH 1.0 for 3 min. 
The envelope of a single E. coli cell contains 2 x 106 LPS molecules constituting 
about 20 femtograms (Minabe et al., 1994).  LPS molecules are of great 
compositional and structural diversity, and yet, the y are built up according to a 







Figure 1.1 Structural features of LPS.  (A) The location of LPS. LPS is on the Gram 
negative bacterial outer membrane. LPS, lipopolysaccharide; PPL, phospholipids. Adapted 
from Prescott et al. (2002).  (B) The structure of LPS. LPS consists of an O-specific antigen, 
a core oligosaccharide and a fatty acid tail called lipid A. The core oligosaccharide, which 
varies from one bacterial species to another, is made up of outer and inner sugar regions.  
Lipid A virtually always includes two glucosamine residues modified by phosphates and a 
variable number of fatty acid chains.  Adapted from Ulmer AJ et al. (2002), with some 
modifications. (Ulmer AJ et al., 2002) (Prescott et al., 2002) 
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Generally, LPS has a tripartite structure comprising three covalently linked 
domains: the O-specific antigen, the core oligosaccharide and lipid A (Figure 1.1B).  
(a) The O-specific antigen is made up of a chain of repeating oligosaccharides of 3 - 8 
units, which are strain-specific and determine the serological identity of the respective 
bacterium (Petsch and Anspach, 2000) .  Therefore, considerable structural diversity 
is noted amongst the O-specific antigen chain structures of LPS from various GNB.  
Furthermore, the major anti-LPS immune response is generally directed to the 
O-chain polysaccharides.  However, the O-specific antigen of LPS is not necessary 
for bacterial growth or survival (Raetz et al., 1988).  (b) The core oligosaccharide 
has an inner KDO (2-keto-3-deoxy-D-mano-octonate)-heptose region and an outer 
hexose region, primarily glucose, galactose and N-acetylglucosamine (GlcNAc) 
(Jansson et al., 1981; Rick, 1987) .  The hexose molecules in the outer core are more 
variable in structure than the inner core.  The KDO sugar is linked directly to the 
lipid A moiety (Rietschel and Brade, 1992).  (c) The minimum structure of LPS 
capable of sustaining bacterial growth and survival consists of the lipid A attached to 
two or three KDO residues (Lynn, 1998) .  Lipid A is the most conserved moiety of 
the LPS molecules derived from diverse strains of GNB.  It is considered to be the 
bioactive centre of the LPS molecule as virtually all LPS-induced biological 
responses are lipid A-dependent in host cells.  The most convincing evidence comes 
from studies of free lipid A (Galanos et al., 1992) and synthetic lipid A (Takayama et 
al., 1983) , both of which show full endotoxic activity.  Lipid A is composed of a 
phosphorylated b1,6-linked D-glucosamine disaccharide that carries variable numbers 
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of asymmetrically placed amide or ester-linked acyl chains.  This structure is the 
minimal requirement for lipid A bioactivity, referring to its cytokine inducing capacity 
(Rietschel and Brade, 1992).  The unique structure of lipid A most likely reflects its 
important roles in the outer membrane assembly and functions, and it ensures 
resistance to phospholipases, etc.   
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1.3 Gram negative bacterial infection and LPS signaling pathway 
During infection, the host innate immune defense s immediately respond to the 
Gram negative bacterial invasion via LPS-induced signal transduction pathways, 
finally resulting in inflammation and septic shock.  The innate immune system 
initiates host defense against the invasive microbial pathogens via specific 
recognition mechanisms (Figure 1.2).  LPS is a pathogen-assoc iated molecular 
pattern of the Gram negative bacteria and it is a key virulence factor.  Upon infection, 
LPS is released from the bacterial cell wall into the blood stream and the LPS-binding 
protein (LBP) binds to LPS via the lipid A moiety (Schumann et al., 1990) .  The 
LBP -LPS complex subsequently interacts with CD14 (Wright et al., 1990), a 55 kDa 
glycophosphatidylinositol (GPI)-linked receptor protein that is found on the surface 
of macrophages, monocytes and neutrophils (Figure 1.2) (Kim et al., 2005; 




Figure 1.2 The host  cellular activation by 
lipopolysaccharide . (a) In plasma, LPS is 
released from the Gram negative bacteria. (b) 
LPS-binding protein (LBP) transfers LPS to 
CD14 and facilitates the interactions of LPS 
with CD14 expressed on the surface of 
monocytes/macrophages or neutrophils. 
Endothelial cells and some other types of 
cells do not express CD14. (c) LPS stimulates 
these cells by binding soluble CD14.  IFN-g, 
interferon g; IL-1, interleukin 1; 
MOF/MODS, multiple organ failure/multiple 
organ dysfunction syndrome; NO, nitric 
oxide; PAF, platelet-activating factor;  
TNF-a, tumor necrosis factor.  Adapted 
from Kamira et al. (1999) with some 





Another LPS sensor molecule is the Toll-like receptor 4 (TLR4) -MD-2 complex, 
which is localized at the host immune cell membrane (Yang et al., 2000).  
LPS-induced signal transduction involves many protein kinases, such as p38 and JNK 
(Sweet and Hume, 1996) , which can lead to the activation of several transcription 
factors such as NF-?B, which in turn activates gene transcription of numerous 
pro-inflammatory cytokines, tissue factors, adhesion molecules and inducible nitric 
oxide synthetase.  Subsequent overproductions of these potent mediators initiate  a 
series of events that lead to clinical manifestations of sepsis.  Amongst the 
pro-inflammatory cytokines, TNF-a plays a critical role in the inflammatory response 
and is often regarded as a hallmark of LPS-induced inflammatory study (Tang et al., 
2005).  Following LPS challenge, the immunological cascade, encompassing CD14, 
TLR, MAPK and NF-kB (Akira et al., 2006; Guha and Mackman, 2001) is swiftly 
activated to sensitize the host to an LPS-induced uncontrolled acute inflammatory 
response that results in septic shock (Figure 1.3) (Li et al., 2006a). 
Endotoxin also interacts with the humoral arm of the immune system. It 
activates both the complement cascade which further fuels the inflammatory response, 
and the coagulation cascade which leads to the development of disseminated 
intravascular coagulation that quickly exhausts the clotting components in the blood 
leading to haemorrhage (Glauser et al., 1991).  
Therefore, the binding of the LPS-receptors to LPS is required to trigger an 
inflammatory response.  Thus, recent studies are directed towards the intervention of 
this step with potential LPS-binding drugs to compete against binding of  
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Figure  1.3.  LPS-stimulated signaling pathways in a host.  LPS binds to the host serum 
protein, LBP, and the LPS-LBP complex is transferred to the receptor, CD14, at the cell 
surface. LPS then interacts with the signaling receptor TLR4, with the adapter protein MD-2.  
LPS stimulates the activation of various signaling pathways, including the IKK-NFkB, p38, 
and JNK pathways.  Furthermore, LPS activates the host immune gene expression via 
translocation of NFkB and AP-1. Subsequently, the cytokine genes are expressed.  
Overproduction of TNF-a and the ILs will lead to septic shock. Adapted from Guha and 
Mackman (2001), with some modifications. (Guha and Mackman, 2001) 
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1.4  Current advances on LPS-neutralizing strategies 
In light of the role played by LPS in septic shock, it is the most prominent 
target for prophylaxis.  Current LPS-neutralizing work explores the development of 
LPS antagonists.  Blocking sepsis at the point of LPS itself is an approach that is 
highly advantageous because it is the most upstream step and the activation of the 
downstream inflammatory cascade may be checked or prevented.  So far, anti-LPS 
strategies under investigation include LPS analogue s, anti-LPS antibodies, and 
LPS-neutralizing proteins or peptides.  
 
1.4.1 LPS analogues 
Investigations into LPS analogues have focused on the biologically active 
moiety, lipid A.  These analogues should maintain the basic features of LPS, or those 
that competit ively bind with host LPS-effectors without activating the host immune 
response.  The first analogue that was discovered was lipid X, the monosaccharide 
lipid A precursor, which inhibits the LPS-induced superoxide production in an in vivo 
neutrophil system (Danner et al., 1987; Takayama et al., 1983). Depending on dosage 
and incubation time, it prevented LPS-induced enhancement of superoxide production 
in an in vitro neutrophil system.  However, the LPS-inhibitory effects are limited and 
may not be beneficial in actual GNB infections (Danner et al., 1993). Simultaneously, 
other researchers focused on the glucosamine disaccharide-based analogues that were 
more potent in antagonizing LPS (Lynn et al., 1991).  Rhodobacter sphaeroides lipid 
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A (RSLA) completely antagonises the endotoxin effects of Salmonella  minnesota 
LPS on phagocytic and endothelial cells at a concentration of five- to ten- fold excess 
of antagonist (Golenbock et al., 1991). These analogues compete with the 
endotoxin/LPS for LBP and deplete the serum of bio-available LBP, thus blocking 
CD14-dependent phagocytic cell activation (Aida et al., 1995) . Other LPS analogues 
reported include E5331 derived from Rhodobacter capsulatus LPS (Christ et al., 
1995), monophosphoryl lipid A (Astiz et al., 1995) and Helicobacter pylori LPS 
(Lepper et al., 2005; Ong, 1999).  However, some of these compounds have limited 
LPS-inhibitory effects and some analogues could still induce a certain degree of  
inflammatory activation (Fujimoto et al., 2005).   
Anionic bacterial phospholipids (see Figure 1.1A) were also used as LPS 
analogues.  Phospholipids are important constituents of both the bacterial and 
mammalian cell membranes.  It is interesting that the composition of phospholipids 
on the membrane of bacteria is rather different from that of mammalian cells  
(Hancock and Rozek, 2002; Hauser and Poupart, 1992; Yamaguchi et al., 2002).  
The mammalian cell membrane comprises mainly phosphatidylcholine (~45% PC), 
phosphatidylethanolamine (~15% PE), phosphatidylserine (~ 5 % PS) and small 
amounts of other phospholipids, most of which are neutral at physiological pH.  In 
contrast, bacterial membranes such as that of Pseudomonas harbor substantial 
amounts of negatively charged phospholipids, such as phosphatidylglycerol (PG), 
besides neutral phospholipids, PE (Figure 1.4 & Table 2) (Gidalevitz et al., 2003; 
Graham and Higgins, 1997) .  The bacterial phospholipids such as PG, which are 
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negatively charged are similar in structure to lipid A of LPS (Lysko and Morse, 1981).  
Both lipid A and anionic phospholipids have negatively charged headgroups and lipid 
tails.  Thus, some anionic phospholipids, for example phosphatidylglycerol (PG), are 
thought to be LPS-analogues.  Purified PG is found to strongly interfere with the 
interaction of LPS with LPS receptors on the host cell membrane, and thereby 
inhibit ing LPS-induced TNF-a  production (Hashimoto et al., 2003; Mueller et al., 
2004; Yu et al., 1997).  However, whether phosphatidylglycerol could be used as 




Figure 1.4 The composition of phospholipids on membranes. ?  represents the mammalian 
cell membrane; ¦  represents the bacterial (Pseudomonas) membrane.  This plot is based on 
information obtained from Graham and Higgins (1997). (Graham and Higgins, 1997) 
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Table 2 The characteristics of four kinds of phospholipids  

























* R1, R2 are fatty acyl chains  
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1.4.2 Anti-LPS antibodies 
Anti-LPS antibodies have been raised to target different parts of the LPS.  The 
first anti-LPS antibodies used in clinical trials were polyclonal human antisera 
obtained after vaccination of volunteers with heat-killed E. coli 0111-mutant J5 
(Ziegler et al., 1982).  The problems of polyclonal antibody preparation and 
difficulties in getting an adequate supply of human antisera led to the development of 
monoclonal antibodies against lipid A (Bone et al., 1995; Greenman et al., 1991).  
The application of some antibodies, against the O-specific antigen is largely limited 
by the fact that the O-specific antigen is antigenically distinct for each strain or 
serotype of bacterial LPS.  It has thus not been possible to create an antibody against 
the whole range of LPS molecules from strains that elicit ill effects.  To circumvent 
the limitations posed by O-specific chain variability, researchers began focus ing on 
antibodies that target conserved epitopes, for example, the core oligosaccharide and 
lipid A moieties on LPS, in the hope of finding antibodies that are cross-reactive to a 
wide variety of heterogeneous GNB.  
Rough strains of bacteria produce LPS lacking O-specific chains.  LPS from 
the E. coli J5 and Salmonella Minnesota R595 rough mutants have been extensively 
used in the development of antibodies targeting conserved epitopes.  Polyclonal 
antibodies directed against the conserved epitopes have been reported to protect 
animals even when challenge d with heterologous GNB (McCabe et al., 1988) . It has 
been hypothesized that these antibodies targeting the conserved epitopes protect by 
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binding LPS and neutralizing its endotoxic activities. Unfortunately, the results from 
laboratory studies and human clinical trials have not been consistently reproducible 
(Greisman and Johnston, 1988) .  
With the advent of hybridoma technology, investigators developed monoclonal 
antibodies (mABs) against the conserved epitopes of LPS in the hope of finding a 
more specific cross-protection therapy than those obtained by the polyclonal antisera. 
Although some monoclonal anti-LPS have undergone several multicentre, 
randomized medical trials, the use of anti-LPS antibodies in clinical practice appears 
to be a failer as shown by the excessive mortality in the treatment arm of a large 
clinical trial (Piercey, 1993). Furthermore, some antibodies like anti-Pseudomonas 
LPS have never shown any potential for protective efficacy (Hatano et al., 1995) .  In 
light of the difficulties and the lack of efficacy of the anti-LPS antibodies, other 
approaches had to be explored. 
 
1.4.3 LPS-neutralizing proteins or peptides 
Numerous proteins and peptides in insects and mammals appear to have 
evolved for the purpose of binding and neutralizing LPS (Bowdish and Hancock, 
2005; Hancock and Scott, 2000; Pristovsek and Kidric, 2004) .  It is thus worth the 
scientific efforts and resources to develop and modify these molecules for use against 
GNB sepsis.  To date, several LPS-binding proteins have been isolated and 
characterized in humans, mammals and other invertebrates (Table 3).  One of the 
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most well-studied LPS-binding protein is bactericidal/permeability-increasing (BPI) 
proteins, isolated by Weiss et al. (1975).  BPI is a 50-60 kDa membrane-assoc iated 
protein with remarkable potency and specificity in its cytotoxicity towards GNB.  
BPI, has been extensively studied and is currently undergoing clinical trials (Elsbach 
and Weiss, 1998) .  It has been reported that the BPI could displace LPS from 
LBP -LPS complex by interacting with the lipid A moiety (Gazzano-Santoro et al., 
1992) and this results in the inhibition of LPS-mediated proinflammatory effects in 
vivo .  (Weiss et al., 1975)  
It was also noted that there were several other proteins containing LPS binding 
domain. It is now well recognized that plasma LPS-binding protein (LBP) and 
membrane CD14 (mCD14) present at the surface of cells of monocytic lineage are 
central molecules of the innate immune system, in response to LPS or to bacterial 
products (Heumann, 2001; Karima et al., 1999). LBP facilitates binding of LPS to 
CD14 and high-density lipoproteins. CD14 is a 55 kDa proteins which exists as a 
glycosylphosphatidylinositol-anchored (GPI) protein on the surface of leukocytes 
(mCD14) or as a soluble protein found in serum (sCD14). CD14 mediates the 
LPS-dependent activation of many cell types including endothelial cells, and 
polymorphonuclear leukocytes (PMN). Complexes of LPS and CD14 thus appear to 
be key intermediates in the cellular response to LPS that underlie septic shock 
(McGinley et al., 1995) .  
Limulus anti-LPS factor (LALF) is a small basic protein of 101 amino acids, 
which binds LPS and has a strong anti-bacterial effect on GNB (Morita et al., 1985) .  
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Hoess et al. (1993) have obtained the crystal structure of LALF. Based on the 
sequence similarity and other evidence, they suggested that an exposed amphipathic 
loop on LALF represents an LPS-binding motif. The amphipathic loop of LALF is 
distinguished by an alternating series of positively charged and hydrophobic residues  
(Hoess et al., 1993) .  
LBP, CD14 and LALF each bind to one molecule of LPS by recognizing its 
lipid A moiety (Hailman et al., 1994; Tobias et al., 1989; Warren et al., 1992) . BPI 
also binds LPS at the lipid A domain, but no literature is available on their  
stoichiometric relationship (Marra et al., 1992). These four proteins possess 
amphipathic regions that are deemed to be sites of interaction with the same  
amphipathic ligand, lipid A. The regions also have numerous basic residues [Lys (K), 
Arg (R)] , some of which are probably involved in ionic interaction with phosphate 
headgroups of lipid A that are essential for the activity of the ligand. In other 
LPS-binding proteins, smaller antimicrobial fragments that were cleaved in vivo were 
discovered. For example, lactoferrin (LF) was found to release a smaller antimicrobial 
fragment called lactoferricin. Similarly, cloning of CAP-18 protein cDNA revealed 
that the identified active smaller antimicrobial fragment corresponded to the 
C-terminal 37 amino acids of a precursor, which might have been cleaved either after 
synthesis or upon exposure to the butyrate treatment.  
 21 
Table 3 Examples of endotoxin-binding proteins that have been isolated and characterized 
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Recently, intense efforts have been made to derive the LPS-neutralizing 
peptides from these proteins, mainly because peptides are less immunogenic, eas ily 
produced by chemical synthesis and their structures are more readily determined.  
Thus, LPS-neutralizing peptides have been derived from the naturally occurring 
proteins such as cationic antimicrobial protein, LPS-binding protein, and serum 
amyloid P component (Table 4) (Arana Mde et al., 2003; de Haas et al., 1998; Hirata 
et al., 1995; Scott et al., 2000; Wasiluk et al., 2004). Hybrid peptides of BPI and LBP 
have also been studied for their therapeutic value  (Marra et al., 1992). These peptides 
derived from parts of the LPS-binding proteins with or without modifications have 
been analyzed for their LPS-binding properties.  It was reported that the 
LPS-binding properties are related to the positive ly charged and basic amino acids on 
the putative LPS-binding sites of these LPS-neutralizing peptides (Agerberth et al., 
1995; White et al., 1995) .  Furthermore, a variety of synthetic  peptides have been 
designed based on the identified LPS binding domains on selected LPS-binding 
peptides and proteins. Based on this strategy, a series of peptides have been rationally 
designed containing the LPS binding sites, and it was shown that amongst these, a 
peptide named V4 is found to harbor strong efficacy for LPS binding compared to 
other synthetic and natural peptides (Frecer et al., 2004).   
In aqueous solutions, binding of the antimicrobial cationic peptides to LPS 
appears to involve a dual-step process: (a) preliminary interaction of the cationic 
amino acids (e.g. lysine, arginine) with the anionic groups of lipid A from LPS 
(phosphate head groups), followed by (b) the stabilization of the resulting molecular 
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complex through hydrophobic interactions involving the fatty acids of lipid A, the 
hydrophobic amino acids (e.g. phenylalanine and leucine), and most likely the alkyl 
chain of lysine or arginine residues as well (Dimarcq et al., 1998; Hancock, 1999) . 
 
 
Table 4 Primary sequence of peptides that bind and neutralize LPS 
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1995) 
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et al., 1995) 
LBP82-108  LPS binding protein  DSSIRVQGRWKVRKSFFK
LQGSFDVSV 
(Battafaraono 
et al., 1995) 
LBP91-105  LPS binding protein  WKVRKSFFKLQGSFD (Taylor et al., 
1995) 
LF-33 Lactoferrin GRRRRS VQWCAVSQPEAT
KCFQWQRNMRKVRGP 












(Gough et al., 
1996) 
PMB Polymyxin B mo-K’TK’K’K’fLK’K’T* (Morrison and 
Jacobs, 1976) 
SAP Serum amyloid P 
component 
EKPLQNFTLCFRA (de Haas et al., 
1998) 
 
* mo: methyl octanoate; K’: diaminobutyric acid; f: D-Phe. 
 
 24 
1.5 Factor C, an LPS biosensor protein in the horseshoe crab  
The evolutionary success of horseshoe crabs over 500 million years attests to 
its strong immune defense mechanisms.  It has relied solely on the innate immune 
defense to thrive in microbiologically challenging ha bitats, where myriads of 
pathogens are found.  The horseshoe crab harbors many proteins/peptides that 
participate in several frontline defense mechanisms to stave off an infection: (a) 
complement cascade protein, like C3 (Zhu et al., 2005); (b) melanization reaction in a 
phenoloxidase -induced production of toxic compounds from a protein like 
hemocyanin (Nagai et al., 2001); (c) antimicrobial peptide defense, like tachyplesin 
(Nakamura et al., 1988) ; and (d) an extremely sensitive blood coagulation cascade 
sensor protein that is triggered by trace levels of LPS, like Factor C (Ding et al., 1993; 
Muta et al., 1991). Amongst these proteins, Factor C functions as a front line defense 
molecule  to fight against the invading bacteria and LPS.  
The horseshoe crab hemolymph contains mainly one type of blood cells called 
amoebocytes, which are extremely sensitive to LPS infection.  The amoebocytes 
release granular components into the plasma to participate in self-defense via blood 
coagulation (Iwanaga and Lee, 2005)  and incapacitation of the invading microbe.  
The amoebocytes contain two kinds of secretary granules, the large and small 
granules.  Studies on these granules suggest that coagulation factors, such as Factor 
C, are localized in the large granules and that the antimicrobial peptides such as 
tachyplesin, are located exclusively in the small granules (Figure 1.5).  In the past 
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decade, the molecular mechanisms of the coagulation cascade have been established 
(Ding et al., 1995; Iwanaga et al., 1994) (Figure 1.6). This cascade is based on three 
kinds of serine protease zymogens—Factor C, Factor B, proclotting enzyme—and 
one clottable protein, coagulogen (Muta and Iwanaga, 1996) . Being at the initial step 
of the coagulation cascade, Factor C functions as a biosensor of LPS capable of 
detecting picogram levels of LPS (Ho, 1983).  LPS from Gram-negative bacteria 
induce the amoebocytes to aggregate and degranulate.  Presumably, LPS-induced 
coagulation cascade represents an important defense mechanism used by horseshoe 
crabs against the invasion of Gram-negative bacteria (Armstrong and Rickles, 1982) .   
The Limulus amoebocyte lysate (LAL) test has been used for decades as a tool to 
detect trace concentrations of LPS in solution (Levin et al., 1970) .  No homologues 
of Factor C have been found in the mammals, although the C-terminal serine protease 
domain has close similarities with human a-thrombin (36.7%) (Mario Antonio A. 
Navas, 1991).  Thus, Factor C is a unique LPS-binding protein found only in the 
horseshoe crab. As a “living fossil” which has survived for several hundred million 
years, the long existence of the horseshoe crab attests to its strong innate immune 
defense ability, which it uses as one of mechanisms of resistance to thrive in 
microbiologically challenging habitats with abundant variety of pathogens.     
Recently, genetic engineering of Factor C in E. coli (Roopashree et al., 1995), 
yeast (Ding et al., 1997)  and mammalian cells (Roopashree et al., 1997) yielded 
recombinant Factor C (rFC) capable of binding of endotoxin. Further cloning, 
molecular manipulation and expression in baculorviral system produce d an rFC with 
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remarkable sensitivity of 0.001 EU/mL endotoxin (Ding and Ho, 2001; Wang et al., 
2002) . The biologicaly functional rFC acts as a biosensor for endotoxin. The rFC 
remains as a zymogen until it encounters trace levels of endotoxin, where it 
unequivocally exhibits full enzymatic activity, indicating the presence of endotoxin in 
a test sample. New microfluorimetric or microcolorimetric assays integrated into the 
rFC assay has allow ed high-throughput screens of LPS in multiple samples. Currently, 
recombinant Factor C has been used in an LPS-assay to sensitively detect LPS (Ding 
and Ho, 2001).  The rFC has been incorporated into the PyroGene kit (Cambrex Inc., 
USA, www.cambrex.com/content/bioscience/CatNav.oid.886.prodoid.PyroGene ).  
Since rFC has extremely high affinity for LPS, it could be a potential 
LPS-neutralizing “drug ” and it is logical to derive LPS binding peptides from the 




Figure 1.5 The amoebocytes of horseshoe crab. Some small defense molecules like 
antimicrobial peptides that have been identified are in small granules, while Factor C and 
other defense molecules are localized in large granules. Adapted from Iwanaga and Lee 




Figure 1.6 The coagulation cascade reaction in the horseshoe crab amoebocyte lysate. In 
the presence of LPS, Factor C is autocatalytically activated to an active form, Factor C’ Factor C’ 
will active the proenzyme Factor B into Factor B’ , which activates proclotting to active 
clotting enzyme. Clotting enzyme then converts coagulogen into coagulin gel clot, which 
traps the invading bacteria. Then clotting enzyme and coagulin clot will be produced. Adapted 
from Ding and Ho. (2001); Ding et al. (1993); Iwanaga et al. (1994). (Ding and Ho, 2001; 
Ding et al., 1993; Iwanaga et al., 1994).  
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1.6 The rationale for derivation of LPS-binding Sushi peptides from Factor C  
     In our lab, we have characterized the LPS binding region of Factor C from the 
horseshoe crab, Carcinoscorpius rotundicauda.  The Carcinoscorpius rotundicauda 
Factor C (CrFC) is a 132 kDa glycoprotein, consisting of a heavy chain (80 kDa) and 
a light chain (52 kDa).  Near the N-terminus of the heavy chain, there are several 
repeats of Sushi domains of ~ 60 amino acids each.  The Sushi domains are also 
known as short consensus repeats (SCR) or complement control protein (CCP) 
domain (Henderson et al., 2001).  By expressing and analyzing the N- and C- 
terminal fragments of recombinant Factor C protein, Ding et al. (1997) revealed that 
the major LPS-binding site in Factor C is located at the N-terminal region.  Then, 
Tan et al. (2000a) reported that the N-terminal fragment (CrFCES) binds LPS with 
high affinity.  Those small fragments in CrFCES were further subcloned and 
expressed (Tan et al., 2000b) . Subsequently, (Wang et al. (2002) demonstrated that the 
Sushi 1 and Sushi 3 domains are the major LPS-binding regions.  Although the 
LPS-binding sites of Factor C have been discovered, it was necessary to define the 
precise  amino acid residues in the Sushi domains that are responsible for interacting 
with LPS.  Based on the understanding of the amino acid sequence in the Sushi 
domains and comparison of LPS-binding motifs of several other LPS-binding 
proteins, Frecer et al. (2000) used computer-aided molecular modeling to show that a 
predominance of lysine and arginine residues occurs in alternation with hydrophobic 
residues, BHBHB (B=basic; H=hydrophobic).  Thus, two 34 amino acid sequences 
containing BHBHB residues were found within the Sushi 1 and Sushi 3 domains of 
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Factor C.  Interestingly, following such a rational approach, Pristovsek and Kidric  
(2004) have further tested various synthetic peptides containing BHBHB motifs and 
noted in agreement with the LPS-binding and ne utralizing capabilities in peptides 
containing Sushi amino acid motifs. (David et al., 2000; Pristovsek and Kidric, 2004).   
The core LPS binding region of Sushi 1 and Sushi 3 domains  reside in these two 
34-mer peptides, henceforth referred to as S1 and S3 peptides (Figure 1.7). 
Furthermore, Sushi peptides have been demonstrated to be anti-LPS molecules (Tan 
et al., 2000b) , which specifically kill an opportunistic gram negative bacterium, 
Pseudomonas aeruginosa (Yau et al., 2001) , while exhibiting minimal cytotoxicity to 
human monocytes, THP-1 (Tan et al., 2000b). This specificity has been thought to be 





Figure 1.7 Factor C and its derived peptides, S1, S3 peptide s. The truncated fragments of 
CrFCES, Sushi 1 domain, Sushi 3 doamin, S1 and S3 peptides  are illustrated as open boxes. 
Adapted from Tan et al. (2000b). (Tan et al., 2000b) 
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However, the detailed molecular mechanisms of action of Sushi peptides and 
various other peptides in interacting with LPS are not well-defined, especially since 
the LPS used in previous studies were based on solid phase, viz, the endotoxin 
molecules were coated on a matrix (Tan et al., 2000b). Furthermore , LPS in solution 
may form heterogenous  aggregates (Bordier, 1981; Kastowsky et al., 1993; 
Labischinski et al., 1985; Snyder and McIntosh, 2000; Snyder et al., 1999).  
Nevertheless, considering the recent report that the aggregated form of LPS is 
biologically more active than free LPS molecules (Mueller et al., 2004) , the effects of 
LPS-binding peptides on the aggregates of bacterial LPS became a subject of study 
for the LPS-neutralizing ability of Sushi peptides.  Thus, a systematic study of the 
interaction of Sushi peptides with LPS was required.  In this work, the molecular 
mechanisms of the interaction between Factor C-derived Sushi peptides and LPS were 
investigated by a series of methods including fluorescence correlation spectroscopy 
(FCS).  FCS is able to measure the fluorescence labeled molecules in a small 
confocal solution volume (Schwille and Haustein, 2004) , and can provide  information 
on the binding and aggregation of different components in a solution sample (Maiti et 








1.7 The objectives 
The main objective  of this thesis was to investigate the molecular basis  of the 
interaction between Sushi peptides and bacterial LPS, and to construct a hypothetical 
model of this interaction. To achieve this, the endotoxin -neutralization capacity of 
Factor C molecule was first examined. The thesis first illus trates the initial attempt to 
gain an understanding of how Factor C which harbors LPS-binding motifs acts to 
neutralize LPS in a cell culture system.   Next, the factors contributing to the 
interaction of Factor C-derived Sushi peptides and LPS were evaluated, and the 
structure-activity relationship of Sushi peptides was analyzed.  At the same time, the 
interaction strategies of Sushi peptides are discussed. Various experimental 
approaches were taken to study the binding between Sushi peptides and LPS in vitro.  
Although the conformational change of peptides was studied, this work does not 
attempt to discover the detailed three dimensional molecular structures of the Sushi 
peptides.  Initially, surface plasmon resonance (SPR), was used to examine the  
realtime bio-interaction of peptides with LPS coated on a biacore chip surface.  This 
method provides a realtime kinetic analysis of the binding affinity of Sushi peptides 
on LPS immobilized on a matrix chip.  However, as LPS molecules exist as 
aggregates in solution, fluorescence correlation spectroscopy (FCS) was applied to 
study the interaction between Sushi peptides and LPS as a solution assay.  The 
merits of FCS are also discussed and compared with other biophysical assays  in this 
work.  Taken together, we employed various methods using different forms of the  
LPS (either in the solution or solid phase) to provide more detailed evidence for the 
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mechanism of the interaction between Sushi peptides and LPS.  Simultaneously, the 
secondary structural conformations of Sushi peptides were  studied by circular 
dichroism (CD).  The importance of the structural conformation for the interaction 
was analyzed.  
Moreover, to unravel the biochemical attributes of LPS that contributes to the 
interaction with Sushi peptides, the negatively charged phospholipid, PG, which 
mimics bacterial membrane lipids  was used to simulate LPS, given that the structure 
of the LPS molecule is complicated and LPS is localized amongst PG on the outer 
membrane.  We investigated not only the effects of the headgroups and the lipid tails, 
but also the effect of the unsaturated nature of the negatively charged phospholipids  
on their interaction with Sushi peptides.  In addition, the LPS neutralizing activity of 
Sushi peptides was tested by recombinant Factor C assay, and the effect of inhibiting 
Factor C activity was assessed.  Furthermore, the importance of the Cys residue on 
the interaction was examined by site-directed mutation. Finally, because the S1 and 
S3 peptides were from different domains of Factor C, the individual mechanisms of 
these two peptides are discussed. 
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Chapter  2     Materials and Methods 
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2.1  Materials 
Cell Titer 96 Aqueous for cytotoxic assay was purchased from Promega (Madison, 
Wis.). Fetal bovine serum (FBS, Low endotoxin-defined) was from Invitrogen 
(Carlsbad, California); Fluorescein -5-isothiocyanate (FITC) was from Molecular 
Probes, (Eugene, Oregon, USA). FITC-LPS from E. coli  strain 0111:B4 was 
purchased from Sigma (St. Louis, Mo.)  Lipid A from Escherichia coli strain F583,  
LPS from E. coli strain 0111:B4, LPS from Escherichia  coli 055:B5 and LPS from 
Pseudomonas aeruginosa were from Sigma (St. Louis, Mo.). p38 and 
anti-Phospho-p38 antibody was from Cell Signaling Technology, Inc. (Denvers, MA). 
pET22b-S3-4mer plasmid was previously constructed in our lab (Li et al., 2003).  
Polyclonal rabbit anti-S3 antibody was raised by our lab. Phorbol myristate acetate 
was from Sigma-Aldrich (Fairlawn, N.J.). Phospholipids: DPPG, POPC, POPE, 
POPG and POPS were from Avanti (St. Louis, MO, USA). Pyrogen-free water was 
from Baxter (Morton Grove, Ill., USA). rFC-based endotoxin detection kit, PyroGene, 
was from Cambrex Inc., MD, USA. R18 (Octadecyl rhodamine  B chloride), 
Rhodamine6G and Rhodamine-PE (Rhodamine labeled PE) were from Molecular 
Probes, (Eugene, Oregon, USA ). R18 labelled LPS was offered from FCS lab from 
Department of Chemistry, National University of Singapore. TNF-a immunoassay kit 
was from PharMingen (San Diego, Calif.).  
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2.2 Peptide synthesis  
Peptides used in this study were synthesized and purified by Genemed Synthesis 
Inc., San Francisco, CA, USA.  The S1 peptide:  
N-GFKLKGMARISCLPNGQWSNFPPKCIRECAMVSS-C, with an MW of 3758 Da, 
corresponds to residues 171-204 of the Sushi 1 domain of the horseshoe crab Factor C.  
The S3 peptide: N-HAEHKVKIGVEQKYGQFPQGTEVTYTCSGNYFLM-C, with 
an MW of 3,892 Da, corresponds to residues 268-301 of the Factor C Sushi 3 domain  
(Accession Number: S77063). The S3-C27S peptide: 
N-HAEHKVKIGVEQKYGQFPQGTEVTYTSSGNYFLM-C, with an MW of 3,871 
Da, was a mutant of S3 peptide. TMR-S1 is S1 labeled at the N-terminus with 
fluorescent probe, TMR (tetramethylrhodamine). TMR-S3 is S3 labeled at the 
N-terminus with fluorescent probe, TMR. All peptides were purified by high 
performance liquid chromatography (HPLC) to >95% purity.  Unless otherwise stated, 
the peptide concentration in this assay refers to the monomeric form. 
 
2.3 Preparation of phospholipid vesicles 
The vesicles were prepared by dissolving the phospholipids in water.  Briefly, 
dry lipids were dissolved in chloroform briefly.  The solvent was evaporated under a 
stream of nitrogen, and the lipids were held under vacuum.  The phospholipids were 
then resuspended in 20 mM phosphate buffer by vortex mixing.  The resultant 
dispersed lipid, at a concentration of 0.5 mM with respect to phospholipids, was then 
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sonicated and extruded through a 50 nm polycarbonate filter to obtain homogeneity in 
the size of vesicles. 
To understand the effect of the peptides on POPG vesicles, two differently labeled 
POPG vesicles were further prepared: rhodamine entrapped vesicles (REV) and 
rhodamine-labeled vesicles (RLV).  Unlabelled POPG was used to prepare vesicles.  
REV was constructed by addition of free Rodamine6G during the vesicle preparation.  
Since Rhodamine-PG is not commercially available, for studies with RLV, 
Rhodamine-PE was mixed with POPG at a ratio of 1:19 by the extrusion technique  
according to Pramanik et al (2000).  Prior to extrusion, a dried lipid film was 
dispersed by vortex-mixing in buffer containing Rhodamine6G/Rhodamine-PE.  The 
REV and RLV were purified from unincorporated Rhodamine6G/R hodamine-PE by 
chromatography through microSpin™ S-200 HR columns (Pharmacia Biotech, 
Uppsala, Sweden) which removed free rhodamine6G/ rhodamine-PE.  The REV and 
RLV were stored at 4°C (Pramanik et al., 2000).    
 
2.4 Molecular weight determination of rFC protein by SDS-PAGE  
Proteins in reducing (with DTT) and non-reducing (without DTT) buffers were 
electrophoresed in 12% SDS-PAGE gel, and detected by staining with Coomassie 
blue. 
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2.5 Molecular weight determination of Sushi peptide s by Tris-tricine gel 
electrophoresis  
Separation of peptides less than 10 kDa is not possible in the traditional 
discontinuous PAGE system.  This is due to the co-migration of SDS and smaller 
proteins, which obscures the resolution.  However, the Tris-tricine method that 
employs modified buffer conditions separates the peptides, thereby improving 
resolution (Schagger and von Jagow, 1987). Peptides in reducing (with DTT) and 
non-reducing (without DTT) buffers were electrophoresed in 15% Tris -tricine gel and 
detected by Coomassie blue staining.  
 
2.6 Western blot analysis of Sushi peptides 
Western blot analysis was performed according to the manufacturer’s instruction, 
using polyclonal rabbit anti-peptide  antibody (the antigen is chemically synthesized 
Sushi peptides) followed by goat anti-rabbit secondary antibody conjugated to 
horseradish peroxidase (HRP; Dako, CA). The blots were visualized by using 
Supersignal West Pico Chemiluminescent Substrate (Pierece, IL) and exposed to 
X-ray film (Fuji, Japan) .  
 
2.7 Expression of the multimers of S3  gene in E. coli 
A recombinant construct of a cassette with 4 repeats of S3 cloned in the pET22b 
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vector (each S3 monomer unit was connected by D-P linked) (Li et al., 2003) , was 
transformed into the E. coli host, BL21, for expression. The colonies were cultured 
overnight in LB medium with 100 µg/mL ampicillin at 37°C, then diluted 1:100 into 
fresh LB medium with 100 µg/mL ampicillin and grown to an OD600nm of 0.6 before 
induction with 0.4 mM IPTG (Promega). The cells were harvested every hour for 12 h, 
and the expressed products were monitored by SDS–PAGE.   
 
2.8 Purification of rS3 monomer peptide  
Bacterial cultures were pelleted at 5000 x g for 10 min at 4°C and resuspended in 
60 mL of lysis buffer containing 20 mM Tris–HCl, pH 8.0 and 0.5 mM DTT. The 
bacterial total proteins were washed with 20 mM Tris–HCl buffer containing 1 M urea 
and 0.5% Triton X-100 after French press (Basic Z 0.75KW Benchtop Cell Disruptor, 
UK) operated at 15 kpsi for four rounds in order to generate >90% cell disruption. The 
inclusion bodies of total proteins were solubilized in 20 mM Tris -HCl with 8 M urea 
at room temperature. Then, the recombinant S3-4mer was filtered and purified by 
anion exchange using ÄKTA explorer (Pharmacia). Two adjacent amino acids, 
aspartate and proline were previously added between each of the S3 units, so as to act 
as cleavable DP linkers for formic acid digestion (Li et al., 2003). The pool was 
washed with 90 % ethanol, dried, dissolved in digestion buffer containing 70% formic 
acid, 6 M guanidine-Cl and digested at 42°C for 72 h. The final products were 
subjected to ethanol precipitation and dissolved in 20 mM Tris–Cl pH 7.3. The 
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cleaved rS3 peptides were then dialyzed overnight against the same buffer using 
dialysis tubing of 1.5 kDa MWCO pore size (Sigma), thus removing the small linkers 
and residual salt. The bulk of the endotoxin contaminant in rS3-1mer was removed by 
Triton X-114 phase separation followed by polymyxin B affinity chromatography 
(Detoxi-GelTM; Pierce) , to remove trace levels of LPS from the rS3.  
 
2.9 ELISA-based LPS-binding assay 
The polysorp 96-well plate (MaxiSorpTM; Nunc) was first coated with 100 µl per 
well of 10 µg/mL (~1 µM) LPS from E. coli 0111:B4 in pyrogen-free 
phosphate-buffered saline (PBS).  The plate was sealed and incubated overnight at 
room temperature.   The wells were aspirated, washed four times with 300 mL wash 
solution (PBS containing 0.05% Tween-20) and blocked with wash solution 
containing 2% BSA at 37oC for 3 h.  After washing twice, increasing concentrations 
of peptides were allowed to interact with bound LPS at room temperature for 3 h.  
Bound peptides were detected by incubation with rabbit anti-S3 antibody followed by 
goat anti-rabbit antibody conjugated with horseradish peroxidase (Boehringer 
Mannheim, Germany).  Each antibody was incubated for 2 h at 37°C.  In the final 
step, 100 µl of peroxide ABTS substrate was added.  The absorbance was measured 
at 405 nm with a reference wavelength of 490 nm.  The values were correlated to the 
amount of LPS bound and peptide present. 
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2.10 Dot-blotting to detect the binding of Sushi 1 peptide with phospholipids  
To determine the specificity of binding of peptides to the 
phospholipids-on-matrix, a PVDF membrane (Biorad, CA) was first spotted with 5 
µL of each of the phospholipids (POPC, POPE, POPG and POPS).  The phospholipid 
spots were evaporated and the membrane was washed three times with water before  
blocking with wash solution containing 3% BSA at room temperature for 3 h (Hanada 
et al., 2003).  After two washings, the fluorescent labeled peptide (TMR-S1) and 
control (TMR) were allowed to interact with the phospholipid dots at room 
temperature for 3 h.  Peptides that were bound to the immobilized phospholipids 
were detected by red fluorescence. 
 
2.11 rFC assay to determine the neutralization of LPS by Sushi peptides  
The rFC in the PyroGene kit was activated by LPS to catalyze the hydrolysis of a 
synthetic substrate to release a fluorescent product which was quantified at excitation 
and emission wavelengths  of 380 and 440nm, respectively 
(CambrexTechnicalManual, 2005).  Thus, this assay can be used to detect and 
quantify the binding of peptide to LPS and its ability to compete against rFC for LPS. 
In a preliminary assay, 50 EU/mL LPS was found to be  an optimal concentration to 
activate the  rFC enzyme. Thus, peptides which bind to LPS to neutralize its endotoxic 
activity were incubated in PBS at different concentrations for 1 h at 37°C with or 
without an equal volume of LPS in disposable, endotoxin -free borosilicate tubes.  
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Fifty microliters of each mixture was then dispensed into wells of a sterile microtiter 
plate (NunclonTM surface; Nunc), followed by the addition of 50 mL of freshly 
reconstituted rFC reagent.  The fluorescence at 440 nm of each well was monitored 
after 30 min.  
 
2.12  Cell culture  
Human monocytes, THP-1 (ATCC:TIB-202) were grown in RPMI 1640 medium 
supplemented with 5% FBS (fetal bovine serum) , penicillin (100 U/mL), and 
streptomycin (100 µg/mL) (Gibco, Life Technology, ML, USA) at 37°C in a 
humidified incubator supplied with 5% CO2.  The cells were maintained at a density 
of 2.5 x 105–6 cells/mL. 
 
2.13 Western blot analyses of p38 and an ti-phospho-p38 
In order to examine the effects of rFC-mediated suppression of LPS-induced 
signaling in host cells, the status of p38 phosphorylation was examined (Guha and 
Mackman, 2001).  Towards this, the THP-1 cells were treated with 10 ng/mL 
(2EU/mL, Sigma) LPS with or without rFC at 37oC for 2 h. The total cellular proteins 
were resolved in 12% SDS-PAGE, and electrotransferred to PVDF membranes.  The 
membranes were blocked in Tris-buffered saline containing 0.05% Tween-20 and 5% 
skimmed milk for 1 h at room temperature, and incubated at 4oC overnight with rabbit 
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anti-p38 or ant i-phospho-p38 antibodies (Cell Signaling Technology, MA, USA).  
Immunoreactive proteins were detected by horseradish peroxidase -conjugated 
goat-anti-rabbit secondary antibody (Dako, CA, USA), and an enhanced 
chemiluminescence reagent (BD Bioscience, MD, USA).  
 
2.14 Suppression of LPS-induced TNF -a? secretion in THP-1 cells 
To obtain monocyte differentiated macrophages, THP-1 cells were prepared for 
experiment by addition of a concentrated stock solution of PMA (Phorbol myristate 
acetate , Sigma, MO, USA) (0.3 mg/mL in dimethyl sulfoxide) to the cell suspension 
to give a final concentration of 30 ng/mL PMA and 0.01% dimethyl sulfoxide.  
PMA-treated cell suspensions were immediately plated into a 96-well microtiter plate 
at a density of 4 x 105 cells/mL and allowed to differentiate for 48 h at 37°C.  
Immediately after stimulation by 10 ng/mL LPS (Rosenfeld et al., 2006) or LPS 
preincubated with various concentrations of proteins or peptides, the culture medium 
was removed; the cells were washed twice with serum-free RPMI 1640 and incubated 
at 37°C.  At indicated times, the culture medium was collected.  Human TNF-a 
concentrations in the supernatants were assayed using ELISA  (BD Biosciences, CA).  
The values were obtained from at least three independent experiments. 
 
2.15 Cytoxicity test of proteins or peptides  
To test the cytotoxicity of proteins or peptides on mammalian cells, 50 mL of 
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THP-1 monocytes at 2 x 104 were mixed with equal volumes of proteins or peptides  
ranging in concentration from 1.0 nM to 10 nM, in medium and incubated for 24 h at 
37 oC.  To determine cytotoxicity induced by the proteins or peptides, 20 mL of 
CellTiter 96 Aqueous One solution Reagent (Promega) was added into each well for 
90 min at 37oC temperature. 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetr
azolium] (MTS) is bioreduced by metabolically active cells into a colored formazan 
product that is soluble in tissue culture medium.  For detection, the absorbance was 
measured at 490 nm.  To determine the ratio of cell lysis induced by proteins or 
peptides, two experimental controls were used.  Complete lysis was achieved by 
incubating cells in PBS containing 0.2% Tween-20.  This absorbance value 
corresponded to the background, as those cells could not metabolize MTS.  The 
second control representing 0% lysis was determined by incubating cells in medium 
only.  The experiment was done in triplicate. 
 
2.16 Circular dichroism (CD) analysis of the secondary structure of Sushi 
peptide s 
CD experiments were carried out using a Jasco-J-715 CD spectropolarimeter. 
Spectra were recorded in quartz cell cuvettes of 0.1 cm path length. The parameters 
used were band width = 2 nm; step resolution = 0.5 nm; response = 1 s; scan speed = 
10 nm/min; scan width = 320–180 nm. The temperature within the sample chamber 
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was maintained at 25°C with a continuous nitrogen flow through. Calibration was 
carried out with D-camphor sulfonic acid.  
 
2.17 Trp fluorescence scanning spectroscopy determination of the  
hydrophobic interaction of Sushi peptide s with LPS 
To investigate the potential hydrophobic interaction between peptide and LPS or 
phospholipids, we measured the fluorescence change due to the tryptophan (Trp) 
residue in S1 (Zhao and Kinnunen, 2002).  The S1 peptide  
(N-GFKLKGMARISCLPNGQWSNFPPKCIRECAMVSS-C) containing a Trp (W) 
residue was used for this fluorescence assay. The fluorescence scanning spectra were 
obtained with a spectrofluorimeter (Perkin Elmer, LS 50B) by using an excitation 
wavelength of 280 nm and the emission was scanned from 290 to 450 nm at a rate of 
10 nm/s.  Each spectrum was the average of 10 scans.  The spectra were 
baseline-corrected by subtracting the blank spectra of the corresponding solutions 
without peptide.  All samples contained 5 µM peptide in 20 mM phosphate buffer 
(pH 7.0), and the concentration of LPS or phospholipids was 100 µM.  For 
fluorescence quenching experiments, acrylamide was added from a 4 M stock solution 
to final concentrations of between 0.05 and 0.5 M.  The quenched samples were 
excited at 280 nm, and the emission was monitored and the peak maximum was 
determined from the wavelength scan in the absence of quencher.  The effect of the 
acrylamide on the fluorescence of the peptide was analyzed using the ratio Fi/F0, 
where Fi is the fluorescence peak intensity of Trp with acrylamide and F0 is the 
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fluorescence peak intensity without acrylamide (Eftink and Ghiron, 1976) .    
 
2.18 Surface plasmon resonance  (SPR) analysis of realtime interaction 
between Sushi peptide  and LPS  
The bio-molecular interaction between LPS and LPS-binding peptide can be 
analyzed with realtime BIA (Bio-molecular interaction analysis), which exploits the 
optical phenomenon of surface plasmon resonance (SPR) (Kim et al., 2005; Zhu et al., 
2003). It is a technology for studying bio-molecular interactions in realtime, without 
labeling any of the interacting partners. In SPR, one of the components in the 
interaction must be immobilized on the surface of a sensor chip and the other flows 
over the surface in free solution (Figure 2.1 A, B.). SPR describes the phenomenon 
when light photons, incident at a solid/lipid interface from the side of the metal, is 
converted into electron density waves or plasmons. Depending on the ratio of the 
refractive index of both the metal and liquid, resonance occurs at a specifc 
combination of angle and wavelength of light, and the intensity of the reflected light 
for that angle and wavelength is the minimum (Figure 2.1 A). When biomolecules in 
an aqueous medium binds to other biomolecules immobilized onto the surface of a 
metal sensor chip, changes occur in the refractive index for the aqueous medium at 
the proximity of the interface. Measurements in SPR detect the change in the angle 
where resonance occurs. In general, the change in refractive index for a given change 
of mass concentration at the surface layer is the same for all proteins and peptides, 
and is similar for glycoproteins, lipids and nucleic acids. The change in SPR signal is 
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recorded in Response Units (RU), which refer the  change in the mass of biomolecules  
absorbed to the surface layer. Realtime measurement of the binding and dissociation 
of the proteins in solution and from ligand immobilized on the sensor chip can thus be 
detected by an increase and decrease in RU, respectively (Figure 2.1B) 
(BiacoreManual, 2000). 
The realtime interaction between different concentrations of peptides and lipid 
A/phospholipids was performed according to Tan et al. (2000a) using biointeraction 
analysis (BIAcore 2000, Pharmacia). EDTA at 10 mM was added to assist the 
formation of a lipid monolayer on the chip (Tan et al., 2000a)   The SPR was 
recorded on an HPA chip coated with E. coli F583 lipid A or individual phospholipids, 
and the phospholipid-coated HPA chip as blocked with skimmed milk.  The 
parameters used were: flow rate of 20 mL/min or 100 mL/min, injection volume of 50 
mL, and dissociation time of 180 s.  The HPA chip was regenerated by a pulse of 0.1 
N NaOH until the SPR reached baseline.  The temperature within the sample 







Figure 2.1 Surface plasmon resonance (SPR) detects changes in the refractive index. (A)  
SPR is an electromagnetic phenomenon that occurs in a thin metal film at an optical interface 
under conditions of total internal reflection. It is observed as a decrease or dip in reflected 
light intensity at a specific angle. SPR technology uses polarized light and can detect subtle 
changes in optical resonance that occurs when molecules bind to, or dissociate from, an 
immobilized target molecule on a sensor chip. (B) Sensorgram of a binding reaction. 
Sensorgram is a continuous, realtime graphical display of the association and dissociation of 
the interacting molecules. The sensorgram enables the realtime, quantitative determination of 
binding kinetics, specificity and affinity of active molecules in a sample. SPR response value 




2.19 Fluorescence correlation spectroscopy (FCS) to de tect the interaction 
between the peptide and LPS in solution 
2.19.1 The basic principle of FCS  
 In this work, the molecular mechanisms of the interaction between Factor 
C-derived Sushi peptides and LPS were investigated by a series of methods including 
FCS.  FCS is a technique that was established thirty years ago. It measures the 
fluorescence of the labeled molecules in a small confocal volume of 20-100 mL 
(Schwille and Haustein, 2004) .  FCS provides one of the many modes of 
high-resolution spatial and temporal analysis of extremely low concentrations of 
biomolecules.  In contrast to other fluorescence techniques, the parameter of primary 
interest is the spontaneous intensity fluctuations caused by the minute deviations of 
the system from thermal equilibrium.  In general, all physical parameters that give 
rise to fluctuations in the fluorescence signal are accessible by FCS.  It is, for 
example, rather straightforward to determine local concentrations, mobility 
coefficients or characteristic rate constants of molecular reactions of fluorescently 
labeled biomolecules in nanomolar concentrations (Schwille and Haustein, 2004).  In 
biophysical applications particularly, FCS gives information about concentration, 
binding, and aggregation of different components in a sample (Maiti et al., 1997; 





Figure 2.2 The scheme of fluorescence correlation spectroscopy  (FCS) setup. (A) The 
exciting radiation provided by a laser beam is directed into a microscope objective via a 
dichroic mirror and focused on the sample. The fluorescence light from the sample is 
collected by the same objective and passed through the dichroic and the emission filter. 
Afterwards, the light is focused onto the detector, preferably an avalanche photodiode or a 
photomultiplier with single photon sensitivity. (B) Fluorescent molecules diffuse through a 
focused laser beam. The fluorescence arising from illuminated molecules is collected with a 
high aperture objective on an optical microscope, through a confocal pinhole, which defines 
the extent of the detection volume along the optical axis (oval). (C) The fluorescence is 
measured with a sensitive single-photon counting detector and fluctuates with time. (D) The 
fluorescence fluctuations are autocorrelated and normalized by the average fluorescence 
squared. These plots show the theoretical shape of the normalized autocorrelation function 
G(t), as a function of the correlation time t.  Adapted from  Schwille and Haustein (2004) 




2.19.2 Application of the FCS for the investigation of LPS binding peptide  
 FCS provided three different parameters in my investigations: (i) The diffusion 
coefficient of the different fluorescent species in the sample.  The diffusion time, t,  
is a measure of the average time a particle needs to traverse the sample  volume.  The 
diffusion time is proportional to the cubic root of the mass.  To distinguish two 
particles in solution, their diffusion times have to differ by a factor 1.6-2, reflecting a 
4-8 fold difference in mass (Meseth et al., 1999; Wohland et al., 2001) ; (ii) The 
average total number of fluorescent particles, NF, in the confocal volume, which is 
directly proportional to the concentration; and (iii) The mole fraction of different 
particles comprising NF when more than one type of particle is present.  At any one 
time, not more than two different particles are present and all measurements could be 
fitted with models assuming one or two particles in solution  (Wohland et al., 1999; 
Wohland et al., 2001).  I therefore adopted the following conventions: t DS is the 
diffusion time of the smaller particle; t DL is the diffusion time of the larger particle 
(t DL > t DS); RL is the mole fraction of the large particles in solution.  The fraction of the 
smaller particles is therefore 1- RL. 
 Two different FCS detection systems for the investigation of LPS binding 
peptide were set up here:  
 (I) Peptide -labeled system: FCS was used to analyze the  binding and 
interaction between Sushi peptides labeled with TMR and LPS .Aurell and Wistrom 
(1998) determined that the average MW of LPS of E. coli is 10 kDa.  Due to the 
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similarity between the relative molecular weights of the two interacting components  
(TMR = 4 kDa & LPS = 10 kDa), potential complexes of Peptide-TMR:LPS with a 
ratio ~1:2.5 cannot be detected by FCS.  However, complexes of peptide-TMR and 
large LPS aggregates , which exist in solution (Neumann et al., 2002) , are readily 
detectable. The diffusion time of a small peptide will increase as it interacts with the 
large LPS aggregates , i.e. , the peptide-LPS aggregates diffuse more slowly than the 
free peptide.  For example, when only peptide-TMR existed in solution, the t DL of 
the particle  was 8.99 x10-5 s; upon addition of LPS aggregates , t DL increased to 2.54 
x10-3 s. This implies that peptide-TMR binds larger LPS aggregates , which slows 
down its diffusion as reflected by the increase in t DL.  The autocorrelation curves of 
peptide-TMR and peptide-TMR:LPS aggregates  are shown by solid and broken lines, 
respectively (Figure 2.3.A).  
 (II) LPS-labeled system: to determine the effect of peptides on the LPS 
aggregates, measurements can be performed with unlabeled peptides on FITC-labeled 
LPS (FITC-LPS).  Recordings were taken at an excitation wavelength of 488 nm and 
calibrations were performed with FITC and FITC-LPS.  Interaction with increasing 
concentrations of peptide would be expected to cause a decrease in the  diffusion time 
(t DL) of the complex as the large FITC-LPS aggregates are disrupted into small 
Peptide:FITC-LPS aggregates.  For example, when only FITC-LPS aggregates were  
present in the solution, the t DL of the particle was 3.31 x10-3 s, and the NF of the 
fluorescence particle was 5.48.  In contrast, the tDL decreased to 1.21 x10-3 s and the 
NF of Peptide :FITC-LPS aggregates increased to 7.81 after a peptide interacted with 
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the FITC-LPS aggregates to disrupt the micellar complex, resulting in smaller 
Peptide:FITC-LPS aggregates.  This result shows that FITC-LPS aggregates were 
disrupted by peptides, which increased the diffusion time as reflected by a decrease in 
tDL.  The autocorrelation curves of the larger FITC-LPS aggregates and the smaller 
Peptide:FITC-LPS aggregates are annotated by solid and broken lines, respectively  





Figure  2.3.  The autocorrelation curves of two fluorescence correlation spectroscopy  
(FCS) detection systems. (A) The fluorescence intensity of S3-TMR and S3-TMR:LPS 
micelles determined by FCS. (B) The fluorescence intensity of FITC-LPS micelles and 
S3:FITC-LPS micelles determined by FCS. (C) Peptide-labeled FCS system: Change in the 
diffusion time of a small peptide as it interacts with the large LPS aggregates.  When only 
TMR-peptide exists in solution,  the t DL of the particle  was 8.99 x10
-5 s; upon addition of LPS 
aggregates, t DL increased to 2.54 x10- 3 s. This implies that TMR-peptide binds larger LPS 
aggregates, which slows down its diffusion as reflected by the increase in tDL.  The 
autocorrelation curves of TMR-peptide and S3-TMR:LPS aggregates are shown by solid and 
broken lines, respectively.  The autocorrelation curves were normalized by the fluorescence 
fluctuations in Figure A. (D) LPS-labeled FCS system: Interaction with increasing 
concentrations of Sushi peptide caused a decrease in the diffusion time (t DL) of the complex 
as the large FITC-LPS aggregates  was disrupted into small peptide:FITC-LPS aggregates. As 
an example, when only FITC-LPS aggregates were present in solution,  the tDL of the particle  
is 3.31 x10- 3 s, the NF of the fluorescence particle is 5.48.  In contrast, the t DL decreased to 
1.21 x10-3 s and the NF of peptide:FITC-LPS aggregates increased to 7.81 after peptide 
interacts with the FITC-LPS aggregates to disrupt the micellar complex, resulting in smaller 
peptide:FITC-LPS aggregates.  This result shows that FITC-LPS aggregates are disrupted by 
peptide, which increases the diffusion time as reflected by a decrease in t DL. The 
autocorrelation curves of the larger FITC-LPS aggregates and the smaller peptide:FITC-LPS 
aggregates are annotated by solid and broken lines, respectively. The autocorrelation curves 
are normalized by the fluorescence fluctuations in Figure B (Li et al., 2004). 
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2.19.3 FCS to monitor the interaction between TMR-Sushi peptide and LPS 
aggregates 
FCS has been used to study the interaction between peptides and LPS. The FCS 
instrument is a self-built system that is centered around a Zeiss Axiovert 200 inverted 
microscope (Carl Zeiss, Germany) and uses an excitation source and Argon-Krypton 
laser (Melles Griot, Carlsbad, CA, USA) which has a 488 nm line for  fluorescein 
excitation and a 530 nm line for TMR excitation.  The dichroic and emission filters 
(Omega Optical, Brattleboro, USA) were 570DRLP and 595AF60 for TMR and 
505DRLP and 535DF35 for FITC.  Further details on the FCS setup and theory are 
described in Wohland et al. (1999) and Krichevsky and Bonnet (2002) , respectively.  
To determine the interaction between Sushi peptide and the LPS aggregates in 
solution, measurements were performed with TMR-Sushi (Sushi peptide labeled with 
TMR) and unlabeled LPS. For example, recordings were taken at an excitation 
wavelength of 530 nm and calibrations were performed with TMR and TMR-Sushi 
peptides.  In this case, the TMR-Sushi peptides concentration was fixed at 50 nM 
while different concentrations of LPS were added.  For sample preparation, the 
protocol described above was used. As a control, TMR was added to a solution of 
LPS aggregates and the interaction was monitored by FCS. The sample solutions were 
prepared at least 2 h before the measurements to ensure that binding equilibrium had 
been reached.  A 50 mL droplet of the corresponding sample was then placed on a 
cover slip just before the measurement.  The background signal in water and in the 
corresponding buffers was less than 0.2 kHz.  All measurements were pre-calibrated 
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with TMR and TMR-S1 to ensure proper performance of the instrument.  For each 
sample, at least 10 independent measurements were recorded.  (Wohland et al., 1999)  
(Krichevsky and Bonnet, 2002) 
2.19.4 FCS to monitor the interaction between Sushi peptide with FITC-LPS 
aggregates 
To determine the effect of Sushi peptides on the LPS aggregates, measurements 
were performed with unlabeled Sushi peptides on FITC labeled LPS (FITC-LPS).  
Recordings were taken at an excitation wavelength of 488 nm and calibrations were 
performed with FITC and FITC-LPS.  In this case, the FITC-LPS concentration was  
fixed at 500 nM while S1 or S3 peptides were added and the concentration of each 
peptide in solution was 10 mM.  For sample preparation, the protocol described 
above was used. As a control, 0.2% Triton X-100, an LPS-solubilizing detergent 
known to be able to disrupt LPS was added to the solution of FITC-LPS and the 
interaction was monitored by FCS. 
 
2.19.5 FCS to measure  the effect of peptide on lipids vesicles 
FCS measurements were conducted at a constant concentration of 50 nM 
TMR-S1 and 5 mM of different phospholipid vesicles.  The sample solutions were 
prepared at least 2 h before the measurements to ensure that binding equilibrium had 
been reached.  A 50 mL droplet of the corresponding sample was then placed on a 
cover slip just before the measurement.  The background signal in water and in the 
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corresponding buffers was less than 0.2 kHz.  All measurements were pre-calibrated 
with TMR and TMR-S1 to ensure proper performance of the instrument (Li et al., 
2004).  For each sample, at least 10 independent measurements were recorded, and 
the mean reading was calculated.  
We examined the interaction between the Sushi peptides and the vesicles (REV 
& RLV) in solution by FCS.  The diffusion times of REV and RLV were monitored 
using FCS.  The measurements were conducted at different concentrations of peptide 
in the presence of 1 mM of phospholipid vesicles.  The anticipated possibilities were: 
(i) if the vesicles remained intact, the diffusion time (t DL) of REV and RLV would not 
change; (ii) if the peptide disrupted the vesicles, the free rhodamine/rhodamine-PE 
would be released from REV/RLV, respectively thus, the t DL of REV and RLV would 
decrease; (iii) the peptide only formed channels on the surface of vesicles, causing the 
tDL of REV to decrease because the entrapped rhodamine in the center of the REV 
would be released through the channels, while the t DL of RLV would remain 
unchanged.  This is because the rhodamine -PE was labeled only on the surface of the 
RLVs (Figure 2.4).  With the help of the fluorescent labeled REV and RLV, one  can 
clearly monitor the peptide-mediated effects on the vesicles in solution (Pramanik et 







Figure 2.4 Rhodamine entrapped vesicles (REV) and rhodamine-labeled vesicles (RLV). 
(A). The conformation of REV and RLV. (B). Three possible effect of added peptide on 
POPG (palmitoyl-oleoyl-phosphatidylglycerol) vesicles:  (i) if the vesicles remain intact, 
the diffusion time (t DL) of REV and RLV will not change; (ii) if the peptide disrupts the 
vesicles, the free rhodamine/rhodamine-PE will be released from REV/RLV, respectively thus, 
the t DL of REV and RLV will decrease; (iii) the peptide only forms channels on the surface of 
vesicles, causing the t DL of REV to decrease because the entrapped rhodamine in the center of 
the REV will be released through the channels, while the tDL of RLV will remain unchanged. 









3.1 Endotoxin neutralization by recombinant Factor C protein (rFC) 
3.1.1 The purity and biochemical status of rFC  
Although many reports have documented LPS-activated Factor C initiation of 
the coagulation cascade (Ding and Ho, 2001; Iwanaga et al., 1994) , no effort had to 
date been made to exploit the high affinity of Factor C to trace the level of LPS in 
endotoxin-neutralization. Here, we examined the efficacy of rFC in preventing LPS 
from activating the host cell. Figure 3. 1 shows that the molecular weight of the rFC in 
non-reducing buffer was about 132 kDa (see arrow in lane 4 and 5).  In contrast, in 
reducing buffer, the rFC displayed two protein bands  of about 80 (heavy chain) and 
50 kDa (light chain), respectively.  These molecular sizes concurred well with the 
native full-length Factor C (132 kDa) and cleaved Factor C fragments from the 
horseshoe crab Carcinoscorpius rotundicauda (Ding et al., 1993).   
 
3.1.2 The rFC prevents LPS from binding with the LPS-binding peptide 
At the initial phase of inflammation, the host LPS-binding protein (LBP) binds 
LPS to form a complex and activates the LPS receptors on the host cells. The 
activation of LPS receptors switches on the inflammation-responsive genes, which 
overexpress to induce endotoxity in the host (Guha and Mackman, 2001). Therefore, 
it was expected that if rFC binds LPS, it would negate the ability of LBP to complex 
with LPS, i.e. , rFC would neutralize the endotoxity of LPS via its competition against 
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LBP. Here, I examined the efficacy of rFC in competiting against LPS-induced 
inflammation. An assay was set up to test the ability of rFC to compete against LBP 
peptide in binding LPS.  LBP peptide, which is derived from the LPS binding motif 
of LBP protein (Reyes et al., 2002) , was used here.  To examine whether rFC and 
LBP peptide compete with each other for LPS, a sensitive and precise rFC 
fluorimetric assay was performed to assess the ability of LBP peptide to bind 50 
EU/mL of endotoxin in the presence of increasing doses of rFC or LBP.  Figure 3.2A 
shows that increasing levels of LBP peptide caused progressive inhibition of the 
LPS-induced rFC activity until at 200 nM wherein, the LBP peptide completely 
inhibited rFC.  In contrast, only 10 nM rFC was sufficient to effectively displace 
LPS from binding 20 nM of LBP peptide as assessed by measuring the rFC enzyme 
activity, which was recorded as the intensity of fluorescence units measured in the 
PyroGene assay (Figure 3.2B).  LBP peptide itself was found to not inhibit Factor C 
activity. These results suggest that rFC and LBP peptide are likely to compete with 
each other for LPS and they each interact with the same motif of LPS.  This also 
suggests that rFC bounds LPS to prevent it from binding to other LPS-effectors, 





Figure 3.1 SDS-PAGE shows the purity and state of rFC in reducing and non-reducing 
buffer conditions.  Lanes: 1, Protein marker; 2 & 3, rFC in reducing buffer (heavy, H and 
light, L chains of Factor C); 4 & 5, rFC in non-reducing buffer (intact Factor C).   
 
 
Figure 3.2 The rFC and LBP peptide compete to bind LPS.  (A) At a fixed rFC 
concentration of 5 nM, the LBP progressively suppresses rFC mediated LPS-binding activity 
measured in fluorescence units of rFC enzyme activity.  (B) 10 nM of rFC was sufficient to  
displace 20 nM LBP peptide from LPS and result in the recovery of LPS-binding by the rFC, 
upon which the rFC enzyme activity is restored.  
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3.1.3 rFC inhibited LPS-mediated phosphorylation of p38 
To better understand the biological significance of the rFC-mediated suppression 
of LPS activity, we used the human monocyte of THP-1 cell line, which constitutively 
expresses the LPS receptors, CD14 and TLR4, at the cell surface.  We confirmed by 
western analysis over the time course of 2 h of LPS stimulation of the mac rophages, 
the p38 (the major member of the MAPK family) was progressively phosphorylated.   
We next examined the effect of rFC on LBP-LPS driven p38 signaling.  Figure 3.3A 
demonstrates that rFC blocked the activation of p38.  The degree of 
phosphorylation/unphosphorylation of p38 was determined from the intensity of the 
bands using a gel imaging software (Quantity One, Bio-Rad).  LPS caused a high 
level of phosphorylation of p38.  In the presence of rFC, the phosphorylation of p38 
was reduced (Figure 3.3B).  The result clearly shows that rFC can inhibit the LPS 












Figure 3.3. rFC inhibits the p38 phosphorylation caused by LPS.  (A) Western blotting 
results of p38. The top panel shows LPS -induced p38 phosphorylation in human macrophages 
over 120 min.  Right panel shows that rFC effectively inhibited the p38 phosphorylation by 
LPS.  (B) Analysis of intensity of each band on Western blot results yielded a quantitative 




3.1.4 Inhibition of LPS-mediated TNF-a  expression  
THP-1 monoc ytes were stimulated with LPS (10 ng/mL, from Sigma), with or 
without rFC (0-10 nM).  TNF-a  expression was quantif ied to determine the 
inhibitory effect of the rFC on the cytokine release.  Figure 3.4 reveals that rFC 
markedly inhibited the activity of LPS that ultimately led to the suppression of the  
inflammatory cytokine TNF-a .  Only 10 nM of rFC was sufficient to almost 
completely block the LPS-mediated TNF-a  production as compared to the negative 
control, medium and the positive control, 1 mM LBP peptide .  Taken together, these 
results correlate well with the potency of the rFC to inhibit the phosphorylation of p38 
caused by LPS (Figure 3.3). 
 
 
3.1.5 The rFC is not cytotoxic to human cells  
The potential toxicity of rFC to mammalian cells was tested by incubating it with 
THP-1 and Hela cells and analyzing using MTS, a compound that could only be 
metabolized by healthy cells. At 10 nM, rFC showed minimal effect on cell 
permeabilization /cytotoxicity (Figure 3.5).  Therefore, rFC can effectively inhibit 




Figure  3.4.  rFC inhibits the LPS -induced TNF-a  production. The LPS concentration is 
fixed at 10 ng/mL, the concentration of rFC ranges from 0.1 to 10 nM, and the concentration 
of LBP peptide (LBP -p) is 100 nM and 1 mM. THP-1 derived macrophages were activated by 




Figure  3.5. rFC shows minimal toxicity to mammalian cells. THP-1 and HELA cells were 




To reveal the biological significance of the LPS-neutralising potency, we 
examined the anti-LPS activity on the human THP-1 cell line monocyte cultures.  
Our results demonstrate d that rFC could neutralize LPS toxicity by inhibiting the LPS 
signaling pathway in host cell.  Therefore, rFC could be a potential LPS-neutralizing 
antidote. Furthermore, it is possible to design and develop efficacious 
LPS-neutralizing drugs from Factor C. However, the Factor C is a large protein from 
horseshoe crab, which could lead to side-effects in the mammalian cell. Compared 
with the large protein, the small peptide is easily synthesized in chemical assay, and 
nontoxic to mammalian cell. Thus, small LPS-binding peptides derived from Factor C 
would be preferable. To this end, Sushi peptides (S1 and S3) were identified and 
characterized to be the LPS-binding domains of Factor C (Tan et al., 2000b). The 
Sushi peptides could be  produced by recombinant genetic engineering or chemical 





3.2 Expression and Purification of recombinant Sushi 3 (rS3) peptide  
Since the rFC molecule exhibited anti-endotoxin properties, it was pertinent to 
test the LPS-neutralising capability of recombinant Sushi peptides which bind LPS. 
Thus, the designed multimers of Sushi 3 (Li et al., 2003) were expressed and the 
recombinant peptide (rS3) was prepared for analy sis of its anti-LPS efficacy with a 
view to investigating its structure-activity relationship.  
 
3.2.1 Expression of rS3 multimer from bacteria clone   
Sushi peptides have been derived from LPS-binding motif(s) of Factor C (Tan et 
al., 2000b) . Recombinant Sushi peptide was first chosen to investigate because the 
production of peptide is cost-effective.  In our lab, we had successfully cloned the 
tandem repeats of S3 gene into the modified vector pET22b-S3-4mer (Figure 3.6) (Li 
et al., 2003).  Thus, the recombinant S3 peptide (Figure 3.7) could be produced by 
purification and digestion of the multimers in vitro.   
Here, recombinant S3-4mer clone containing 4 tandem repeats of S3 was cultured 
and rS3-4mer protein was purified and acid-digested to yield rS3 monomers. The 
rS3-4mer of 18.4 kD was expressed successfully, and the expression level was higher 






Figure 3.6 Schematic representation of the multimerization of S3 gene using vector 
pET22b. The Asp-Pro (D-P) linker site was introduced into the S3 primers, and the amplified 
gene of the repeated S3 primer was previously linearized with BbsI, allowing the fragments to 
S3 primer self-ligate directionally, thus, giving rise to S3-4mer. These multimeric inserts were 








S3    HAEHKVKIGVEQKYGQFPQGTEVTYTCSGNYFLM 
rS3   PHAEHKVKIGVEQKYGQFPQGTEVTYTCSGNYFLMD 
 
Figure  3.7 The amino acid sequences of the S3 and recombinant S3 peptide .  The 
proline (P) and aspartate (D) residues flanking the rS3 sequence act as linkers, which were 





Figure 3.8 SDS-PAGE analysis of the total protein from E. coli. Lanes 1, Bacteria  
induction by 0.4 mM IPTG; 2, Bacteria control; M: molecular weight protein marker. 
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3.2.2 Production of recombinant S3  monomer (rS3) 
Since the theoretical calculated pI of S3-4mer is 6.0, anion exchange 
chromatography with Q-Sepharose fast flow resin was used to purify it. Figure 3.9 
shows that purification of rS3-4mer by stepwise salt elution (0 to 10 mM to 300 mM 
to 1 M) instead of linear salt concentration elution enriched the rS3 tetramer in to peak 
II. 
It is to be noted that two adjacent amino acids, aspartate and proline flanking the 
S3 units on the tetramer, act as cleavable DP linkers.  The DP linkers were digested 
by formic acid. After 70% formic acid digestion, rS3-4mer was cleaved between D-P 
links yielding the 4 rS3 tandem repeats into rS3 monomeric peptide  (Figure 3.10A ). 
Western analysis shows that rS3-4mer and rS3 were specifically recognized by S3 









Figure 3.9 Purification of rS3-4mer.  (A)  Q-Sepharose fast flow column chromatography 
of rS3-4mer-rich fraction.  (B) SDS-PAGE analysis of Q-sepharose chromatography 
rS3-4mer-rich fraction fractions. Lanes  M, protein marker ; 1&2, peak I; 3&4, peak II; 5&6, 









Figure 3.10 Purified rS3 peptide.  (A) Tricine-PAGE of rS3-4mer and rS3 monomer. Lanes 
1:  rS3-4mer; 2: rS3 monomer. (B) Western-blot ana lysis of rS3-4mer and rS3 monomer.  
Lanes 1: rS3-4mer; 2: rS3 monomer. 
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3.2.3 rS3 forms dimer linked by an intermolecular disulfide bond 
The molecular weight of rS3 peptide was analyzed by mass spectroscopy. It was 
very interesting to note that the peaks of the peptide fingerprints appeared at about 8.2 
kDa, which is two fold of the theoretical molecular weight of rS3 of 4.1 kDa (Figure 
3.11). Thus, rS3 peptides could form dimers in solution.  Moreover, the disparity of 
these peaks is 28 Da, which suggests rS3 peptide is modified into methyacrylated 
forms by formic acid, which was used to digest the rS3 multimers to release rS3 
monomers.   
In order to confirm the dimerisation, the Tricine gel electrophoresis was applied 
to analyze. Figure 3.12 shows that the molecular weights of the rS3 peptides in 
non-reducing buffer are about 8 kDa.  In contrast, the molecular weights of the rS3 
peptides in reducing buffer were about 4 kDa.  This suggests that under 
physiological conditions, the S3 peptides exist as dimers linked by intermolecular 
disulfide bonds.  Thus, Tricine gel electrophoresis was consistent with the MS 
spectrum. It was noted that there is also one cysteine on the chemically synthesized 
S3. Thus, whether chemically synthesized S3 peptides also form dimers like rS3, 






Figure 3.11. Q-TOF mass fingerprints of the rS3 peptide. * points to the mass of 8260 




Figure 3.12.  Tricine PAGE electrophoretic analysis of rS3 peptides under 
non -reducing and reducing conditions.  Lanes M: peptide molecular weight markers; 1: 
rS3 (non-reducing); 2: rS3 (reducing). The results suggest that the rS3 peptide forms a dimer  
via an intermolecular disulfide bond. 
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3.2.4 The secondary structure of rS3 
To investigate the secondary structures of rS3, CD spectra were obtained in 
aqueous buffer. As shown in Figure 3.13, rS3 harbors similar apparent specific 
secondary structures in aqueous buffer compared with chemically synthesized S3 
peptide: both rS3 and chemically synthesized S3 peptide formed stable secondary 
structures. However, the CD spectrum of rS3 was not identical to that of the 
chemically synthesized S3 peptide. For example, the minimum ellipticities of rS3 and 
chemically synthesized S3 peptide are dissimilar at the same wavelengths.   This 
dissimilarity may be attributable to the additional Asp and Pro amino acids (DP 
linkers flanking the S3 sequence) and the methylacrylation in the rS3 peptide.    
 
 
Figure 3.13 CD spectra of S3 peptides in the presence of 10 mM phosphate buffer, pH 
7.0.  The conformational changes in the secondary structure of the rS3 (        ) and 
chemically synthesized S3 peptides in buffer  (       ) were recorded in buffer. 
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3.2.5 The rS3 inhibits LPS-induced recombinant Factor C activity less 
efficiently 
To examine the biological functionality of rS3 peptides, Factor C assay was used 
to assess the activity of S3.  Compared to the chemically synthesized S3 peptide , the 
rS3 peptide inhibited the LPS-induced recombinant Factor C activity to a lesser extent 
(Figure 3.14A).   
 
3.2.6 The rS3 inhibits LPS-induced TNF-a production less efficiently than 
chemically-synthesized S3 peptide  
The ability of rS3 and S3 peptides to inhibit the TNF-a production induced by 
endotoxin was also tested.  Compared to the chemically synthesized S3 peptide , the 
rS3 peptide causes much less inhibition of the LPS-induced recombinant Factor C 











Figure 3.14 The neutralization of LPS by rS3 peptide. (A) Inhibition of the LPS-induced 
recombinant Factor C in the PyroGene assay.  Binding of the peptides to LPS competitively 
inhibits the LPS-induced recombinant Factor C activity.  Compared to chemically 
synthesized S3 peptides (S3), rS3 shows lower ability to inhibit LPS activity. (B) Sushi 3 
peptides inhibit the LPS-induced TNF-a production. The LPS concentration is fixed at 10 
ng/mL. THP -1 derived macrophage was activated by LPS and Sushi peptides together during 
6 hours, and the production of TNF-a  was detected by anti-TNF-a ELISA. Compared to 
chemically synthesized S3 peptides (S3), rS3 shows lower ability to neutralize LPS toxicity.  
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Although rS3 was efficiently expressed and purified, its biological functions 
including anti-LPS activity appeared less efficacious compared to the chemically 
synthesized form of S3. Whether this is attributable to the extra D and P residues  
flanking the rS3 sequence or the methylacrylation in the rS3 peptide  remains to be 
determined. Nevertheless, in the scope of this thesis, further investigations were 
performed using chemically synthesized Sushi peptides. From this point onwards, this 
thesis focused on the use of chemically synthesized S1 and S3 peptides for the 
structure-activity relationship study to elucidate the mechanism of the interaction 
between the  Sushi peptides and LPS.  
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3.3 The importance of S3 peptide dimerisation to its interaction with LPS 
rS3 peptide formed a dimer linked by an intermolecular disulfide bond in aqueous 
phase (Results section 3.2). The disulfide bond was linked by the cysteine on rS3 
monomer (Figure 3.12). Because chemically synthesized S3 also contain ed one 
cysteine, this peptide could also prospectively form a dimer.  In order to gain a 
global perspective on the tolerance of cysteine residues in S3 to amino acid 
substitutions, a mutant peptide named S3-C27S (where cysteine 27 was changed to 
serine, C27S), was synthesized (Figure 3.15A) and the structure-activity relationship 
was analyzed in this section.  
The intermolecular disulfide bond is very important for stabilizing the structure of 
peptides. The secondary structure prediction suggests that S3 peptide is random based 
on the analysis of amino acid sequence (Figure 3.15 A). However, the cysteine of the 
S3 peptide could stabilize the structure of the peptide if it forms a disulfide bond, 
especially since the cysteine  residue is on the C-terminal hydrophobic motif of S3 
(Figure 3.15B), which is crucial in the binding of peptides with LPS. Bioinformatic 
analyses of S3 and the S3-C27S mutant predicted that the (a) secondary structure, (b)  
hydrophobic profile and (c) helicity of S3 were very similar to each other.  This may 
be because the predictions were based on the primary amino acid sequence without 






















Figure  3.15 The secondary structure prediction and hydrophobic profile analysis of S3 
peptide. (A) The secondary structure prediction of the S3 and S3-C27S peptides by the 
software Profsec. (B) The hydrophobic profile of the S3 and S3-C27S peptides computational 
analysis by DNAman software. (C) The helical wheel prediction of the S3 and S3-C27S 
peptides by the online software from http://kael.net/helical.htm. The shaded residues are 
hydrophobic amino acids. 
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3.3.1 The bioactive S3 peptide forms dimers via intermolecular disulfide bonds 
Figure 3.16 shows that the molecular weights of the S3 and mutant S3-C27S 
peptides in non-reducing buffer are about 8 kDa and 4 kDa, respectively.  In contrast, 
the molecular weights of the S3 and mutant S3-C27S peptides in reducing buffer were 
about 4 kDa.  This suggests that under physiological conditions, the native S3 
peptides existed as dimers linked by intermolecular disulfide bonds.   
Furthermore, FCS measurements showed that the number of fluorescent particles, 
NF, was doubled (Figure 3.17) when DTT was added to a solution of 50 nM TMR-S3.  
This indicated that the S-S bond between two S3 peptides was broken by DTT, which 





Figure  3.16 The S3 peptide forms dimers via an intermolecular disulfide bond on PAGE 
gel. Tricine PAGE electrophoretic analysis of S3 and S3-C27S peptides under non-reducing 
and reducing conditions.  Lanes M: peptide molecular weight markers; 1: S3 (non-reducing); 





Figure 3.17 The TMR-S3 peptide forms dimers via an intermolecular disulfide bond in 
solution. Experimental fluorescent particle number , NF, for TMR-S3 labeled peptides  in 
phosphate buffer, pH 7.4 with or w ithout DTT. 
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3.3.2 Disulfide bond stabilizes S3  
Upon addition of DTT, the CD spectrum of S3 change d significantly with the loss 
of negative peaks at 205 nm and 215 nm (Figure 3.18).  These 2 peaks most likely 
represent stable secondary structures such as a-helices and ß-sheets.  Moreover, the 
minimum ellipticity is above 200 nm.  This increase in the absolute values of mean 
residue ellipticity may be due to fewer monomeric conformers in solution and the 
stabilization of the dimer.  The content of secondary structure elements suggests 
distinctive dimers of S3 with a mixture of a-helix and b-sheet.  In contrast, the 
S3-C27S mutant peptide adopts a random coil conformation in phosphate buffer, pH 
7.0, with the single minimum ellipticity observed at 195–200 nm, which is close to 
the spectrum of the S3 monomer (in DTT) under reducing condition in the presence of 
DTT. Thus, the disulfide bond formation between each S3 monomers (Figure 3.16 
&3.17) s tabilizes a secondary structure of the S3 dimer. Thus the structural-activity of 





Figure  3.18 CD spectra of 10 µM S3 peptides in the presence of 10 mM phosphate buffer, 
pH 7.0 (PBS).  The conformational changes in the secondary structure of the S3 monomer 
with DTT (        ); S3 dimer in buffer (     ) and mutant S3-C27S (        ) were 




3.3.3 S3 dimer exhibits higher affinity for the endotoxin molecule   
Anti-S3 antibody recognized both the S3 and S3-C27S peptides (Figure 3.19A).   
The ELISA-based LPS-binding assay revealed different binding capabilities between 
S3 and S3-C27S for LPS with the former binding much better (Figure 3.19B).  
Furthermore, at 2 µM, the S3 peptide reached saturation for binding to LPS, whereas  
the S3-C27S peptide continued to increase linearly.  Under these conditions, the 
native S3 was  dimeric while S3-C27S remained monomeric.  This suggests that the 
S3 dimer ha d a higher affinity for  LPS than the S3-C27S monomer.  Realtime binding 
analysis shows that the interaction between S3 and lipid A reached equilibrium during 
the injection of the sample  through the biacore system. To compare the affinity of the  
Sushi 3 peptides for E. coli lipid A, different kinds of peptides at the same 
concentration in buffer were injected across a lipid A-coated HPA chip.  The 
sensorgrams revealed that the SPR signal intensity increased as a function of the 
concentration of the peptide bound to the lipid A immobilized on-chip (Figure 3.19C).  
This indicates that the amount of peptide bound to lipid A was related to the affinity 
of the peptide for  lipid A on the chip .  At the same concentration, S3-dimer achieved 
2-fold higher response units than the S3-C27S or S3 monomer, viz, S3 treated with 
DTT (Figure 3.19C).  The affinity of S3 dimer to the negatively charged lipid A was 
thus higher than that of S3 monomer , which was similar to what had been obtained by 
ELISA.  To exclude the possibility of the direct effect of DTT on the SPR signals, 
the binding interaction between S3-C27S in DTT and lipid A was performed.  No 
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significant change in affinity was observed between S3-C27S alone and S3-C27S in 
DTT.  This indicates that intermolecular disulfide-bonding plays a key role in the 










Figure 3.19 S3 dimer exhibits strong binding capacity for LPS. (A) ELISA using varying 
concentrations of native S3 peptide and mutant S3-C27S peptide coated on 96-well plates.  
The amount of bound peptides was determined by rabbit anti-S3 antibody and quantitated by 
ABTS substrate.  The average of OD405nm values of the triplicate samples was calculated and 
plotted with the corresponding concentrations of the peptides. (B) ELISA-based LPS binding 
assay. LPS was coated overnight on 96-well plates.  Varying concentrations of peptides were 
allowed to interact with the immobilized LPS.  The amount of bound peptides was 
determined by rabbit anti-S3 antibody and quantitated by ABTS substrate.  The average of 
OD405nm values of the triplicate samples was calculated and plotted with the corresponding 
concentrations of peptides. (C) The sensorgram depicting the realtime interaction between 
Sushi peptides  and the immobilized lipid A.   Fifty microliters of 5 mM peptides were 
injected, result ing in a sustained increase in the relative response unit (RU).  During the 
dissociation phase, pyrogen-free buffer was introduced at a flow rate of 20 µL/min.  The 
HPA chip surface was regenerated by a pulse of 100 mM NaOH. 
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3.3.4  FCS shows that the S3 dimer binds avidly to and disrupts LPS 
aggregates in solution 
Molecular interactions between two different molecules (LPS and S3 peptide) can 
be monitored by the diffusion time (t DL), and the concentration of fluorescent 
particles (NF).  In both of FCS experiments, one of two interacting components was 
labeled by a fluorescent dye, viz, either TMR-S3 (Figure 3.20) or FITC-LPS (Figure  
3.21). Upon binding of a small labeled peptide like TMR-S3 to large LPS aggregates, 
the change in diffusion time was readily detected.  In the absence of LPS aggregates, 
only one diffusion time was detected, representing the value of unbound, freely 
diffusing TMR-S3. In the presence of LPS, the TMR-S3 bound LPS aggregates  
showed an increase in the average diffusion time of the sample (Figure 3.20).  Proper 
fits were obtained only when assuming at least two different particles in solution: 
unbound TMR-S3 (or small TMR-S3:LPS oligomeric complexes that were not 
sufficiently different in mass to be detected) and TMR-S3:LPS micellar complexes.  
The change in the LPS aggregates during the interaction between FITC-LPS and S3 
dimer was reflected by a decrease in tDL w ith a concomitant increase in the particle 
number, NF, (Figure 3.21) during which the S3 peptide bound to FITC-LPS 
aggregates to disrupt their micellar structure. 
Figure 3.20 compares the binding relationship between TMR-S3 and LPS, 
showing that TMR-S3 dimer had stronger affinity for LPS than for TMR-S3 monomer.  
This result is consistent w ith those obtained from SPR analyses. Thus, at the initial 
low concentrations of TMR-S3, the free form of TMR-S3 was the predominant  
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fluorescent species.  During the  course of the interaction, the percentage of the 
complex was continuously increased as the ligand concentration was increased, as 
demonstrated by the increase in RL.  A concomitant increase of t DL show ed that with 








Figure  3.20 Determination of the  stoichiometry of interaction between LPS and TMR-S3. 
The concentration of fluorescent particles /complexes was measured for reaction mixtures 
containing S3-TMR and increasing concentrations of LPS.  The S3-TMR was held constant at 50 
nM.  For S3 dimer (? ), or S3 in  DTT (¦ ) and the concentrations increased from 0 to 1 mM.  (A) 
Compared to S3 monomer, the S3 dimer caused more rapid increase in  t DL, which is the number of 
large particles in solution.  (B) RL which is the ratio of large particle s, increased more rapidly 
with S3 dimer than with S3 monomer.  (C) NF of S3 monomer was two times greater than that of 
S3 dimer.  All data points are averaged over 10 experiments.   The typical spectrums are 
shown in Materials and Methods, Figure 2.3A. 
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To investigate the S3-induced change in LPS aggregates , FITC-LPS was used 
in FCS experiments. A two-component fitting model was employed.   The small 
component was free FITC-LPS (including FITC-LPS:S3 complexes), while  the large 
component represented FITC-LPS aggregates (including FITC-LPS aggregates:S3 
complexes).  In the absence of S3, large fluorescent FITC-LPS aggregates were  
present.  During the interaction, the t DS was kept constant at 9.8 x 10-5 s, while the 
tDL and RL progressively decreased as the concentration of S3 peptide was increased, 
indicating that the S3 dimer interacted with and perturbed the large LPS aggregates  
while NF increase d.  S3 dimers rather than S3 monomers resulted in fewer LPS 
aggregates (Figure 3.21). By comparison to S3, high concentrations of magainin, a 
known LPS-binding peptide (Rana and Blazyk, 1991)  decreased t DL and increased the 
particle number NF, which suggests that magainin can also disrupt LPS aggregates.  
On the other hand, S3-C27S mutant and S3 monomer did not cause a significant 
change to t DL and NF remained constant (Figure 3.21), suggesting that the S3 
monomer is incapable of disrupting the LPS aggregates even at high concentrations.   
As a system control for FCS measurements, it was shown that Triton X-100 
interactions with LPS aggregates  differed from those of the S3 monomer (Figure  
3.21).  Like the S3 dimer, 0.2% Triton X-100 interacted with FITC-LPS to decrease 
tDL, and increase NF.  The disruption of LPS aggregates by Triton X-100 
demonstrates the bona fide observation of disruption of LPS aggregates seen under 




Figure 3.21 Determination of the stoichiometry of FITC-LPS aggregates and Sushi 3 
peptide s interaction. The concentration of fluorescent particles was measured for samples of 
FITC-LPS under different conditions.  The FITC-LPS was held constant at 500 nM.  The 
concentrations of peptide and Triton X-100 were 10 mM and 0.2%, respectively.  (A) In a 
control experiment with FITC-LPS alone, and FITC-LPS in 5 mM DTT, the t DL were 3.31 
x10- 3and 2.59 x10- 3, respectively.  In the case of S3 dimer, the t DL decreased to 1.21 x10
-3.   
The interaction between FITC-LPS and magainin or FITC-LPS and Triton X-100 exhibited 
similar trend of decreasing tDL.  This indicated that all three abovementioned LPS-active 
agents (S3 dimer, magainin and Triton X-100) caused the reduction of the diameter of 
fluorescent particles  of FITC-LPS. This is analogous to the perturbation of the LPS 
aggregates.  In contrast, interaction between FITC-LPS and the same concentrations of 
S3-C27S and S3 (in DTT), did not change t DL significantly. (B) In a control experiment with  
FITC-LPS and FITC-LPS in 5 mM DTT, the RL were 43.69% and 43.41%, respectively.  In the 
presence of S3 dimer, the RL of FITC-LPS decreased to 16.22%.  This is similar to FITC-LPS in 
magainin, and FITC-LPS in Triton X-100.  This represents the dis ruption of FITC-LPS micelles, 
resulting in the release of small fluorescent particles such as free FITC-LPS molecules.  (C) In 
contrast, NF did not change significantly during interactions between FITC-LPS and the same 
concentrations of S3-C27S and S3 in DTT, where the NF values were 5.18 and 4.56, 
respectively.  In the presence of S3 dimer, the NF increased to 7.41.  Magainin and Triton 
X-100 affected a similar increase in NF values .  All data points are average d over 10 




3.3.5 The S3 dimer inhibits LPS-induced recombinant Factor C activity  
To examine the biological functionality of S3 peptides, a sensitive and precise 
fluorimetric assay was used to assess the ability of S3 and S3-C27S peptides to bind 
50 EU/mL of endotoxin (Cambrex, MD).  Compared to the mutant S3-C27S peptide 
which exists as a monomer, the dimeric S3 peptide causes 10-fold greater inhibition 
of the LPS-induced recombinant Factor C activity (Figure 3.22).  The 50% inhibition  
values of the two peptides were determined to be 1 µM for S3 and >10 µM for 
S3-C27S. 
 
3.3.6 The S3 dimer inhibits LPS-induced TNF-a production  
The ability of S3 and S3-C27S peptides to inhibit the TNF-a production induced 
by endotoxin was also tested.  Compared to the mutant S3-C27S peptide which 
exists as a monomer, the dimeric  S3 peptide caused higher inhibition of the 
LPS-induced recombinant Factor C activity (Figure 3.23). However, there appeared to 
be some variation in rFC and TNF-a  assays. Comparing Figure 3.22 and Figure 3.32, 
it is obvious that the same S3 peptide could neutralize LPS toxicity quite differently  
compared with S3-C27S. This could be due to the interaction of some unidentified 
serum factors with peptides, which effectively reduces their availability for binding to 




Figure  3.22 Inhibition of the LPS-induced recombinant Factor C by Sushi 3 peptides in 
the PyroGene assay.  Binding of the peptides to LPS competitively inhibits the 
LPS-induced recombinant Factor C activity.  Compared to S3-C27S, S3 dimer shows 




Figure 3.23   Sushi 3 peptides inhibit the LPS-induced TNF-a  production. The LPS 
concentration is fixed at 10 ng/mL. THP-1 derived macrophage was activated by LPS and 
peptides together during 6 hours, and the production of TNF -a  was detected by anti-TNF-a 
ELISA.  
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In section 3.4, we have documented the molecular interaction between the S3 
dimer peptide and LPS.  In consideration of several biochemical approaches that 
have been employed to study the structure-function relationship of S3 peptide , we 
have demonstrated the critical role of the intermolecular disulfide bond in the dimeric 
S3 peptide, which is probably responsible for its detergent -like properties, enabling it 
to bind avidly to LPS, and equipping the S3 dimer to preferentially disrupt the LPS 
aggregates. Besides S3, Sushi 1 (S1 peptide) is another Factor C-derived peptide. In 




3.4 Sushi 1 (S1) peptide interacts with LPS as a monomer 
S1 peptide has 3 cysteine residues (Figure 3.24A ), two of which are adjacent to 
the C-terminal hydrophobic motif of S1 peptide (Figure 3.24B). Therefore it is 
possible that there are potential intermolecular disulfide bonds between S1 monomers. 
The helical wheel prediction is shown on Figure 3.24C. The disulfide bond formation 
could change the helical wheel conformation and secondary structure and 
amphipathicity of S1 peptide. Therefore, whether the intermolecular disulfide bond is 














Figure  3.24 The secondary structure prediction  and hydrophobic profile analysis of S1 
peptide. (A) The secondary structure prediction of the S1 peptide by the software PROFsec. 
(B) The hydrophobic profile of S1 peptide by computational analysis by the software 
DNAman. (C) The helical wheel prediction is by the online software from 
http://kael.net/helical.htm. The shaded residues are hydrophobic amino acids.  
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3.4.1 The S1 peptide is active as a monomer 
Figure 3.25 shows that the molecular weight of the S1 in both reducing and 
non-reducing buffer remained at 4 kDa. This suggests that contrary to expectations, 
under physiological conditions the S1 peptide s were monomers without 
intermolecular disulfide bond. 
 
3.4.2 S1 peptide has a random structure in solution 
Here, we used CD measurements to examine the secondary structure of S1 
peptide .  In aqueous solution, S1 adopted a random coil conformation as shown by 
the single minimum at below 200 nm (Figure 3.26).  Because, intermolecular 
disulfide bond could help to stabilize the secondary structure of a peptide, the results 
indicate that there was no intermolecular disulfide bond formed between S1 
monomers.  This was consistent with the results obtained from Tricine PAGE gel 





Figure  3.25 The S1 peptide is monomer on  the Trinicne gel. Tricine PAGE electrophoretic  
analysis of S1 peptides under non-reducing and reducing conditions.  Lanes M: peptide 
molecular weight markers; 1: S1 (non-reducing); 2: S1 (reducing). 
 
 
Figure 3.26 CD spectra of S1 peptide in buffer. Only a single minimum is observed at 
below 200 nm, indicating that the secondary structure of S1 is random. 
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3.4.3 Realtime biointeraction between S1 and lipid A  
Figure 3.27 shows a binding profile of S1 peptide to endotoxin.  We 
immobilized the lipid A on a biacore HPA chip activated with a hydrophobic surface.  
Unique biphasic association and dissociation profiles were observed when S1 peptide 
was passed over the microfluidic surface of the biacore chip  coated with lipid A, 
suggesting the binding of S1 to the immobilized ligand.  Such realtime 
biointeraction analysis measured as surface plasmon resonance (SPR), of the binding 
between S1 and lipid A was carried out to yield a set of sensorgrams showing the 
profiles of interaction between different concentrations of S1 and lipid A. The 
sensorgrams revealed that the signal intensity measured in response unit (RU) 
increased as a function of the concentration of the peptide bound to the immobilized 
LPS.  This indicates that the amount of peptide bound to the LPS is related to the 
affinity of the peptide for the chip. The response unit of S1 increased at dosage 




Figure  3.27 A sensorgram depicting the interaction of S1 with immobilized lipid A.  
Aliquots of 100 mL each of three concentrations (1, 2, 5 mM) of S1 peptide were injected over 
an HPA chip which was immobilized with LPS.  The S1 peptide interacted with the lipid A 
and resulted in a sustained increase in the relative response unit.  During the dissociation 
phase, pyrogen-free buffer was flown through the microfluidic surface at 20 µL/min.  The 
surface was regenerated by a pulse of 100 mM NaOH prior to each injection. 
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3.4.4 TMR-S1 peptide binds LPS aggregates in solution 
Figure 3. 28 compares the binding relationship between TMR-S1 and LPS, 
showing that TMR-S1 but not TMR itself had affinity for LPS.  Thus, at the initial 
low concentrations of TMR-S1, the free form of TMR-S1 was the predominant  
fluorescent species.  During the course of the interaction, the larger fluorescent 
complex formed as the TMR bound the unlabelled LPS aggregates, as demonstrated 
by the increased t DL.  A concomitant increase in t DL shows that with LPS added, 
larger TMR-S1:LPS aggregates were formed.  The propensity of LPS to form larger 
aggregates at higher concentrations had been reported in literature (Aurell and 
Wistrom, 1998).  
 
3.4.5 Trp fluorescence Detection of the hydrophobic interaction between S1 
peptide and LPS  
The presence of one Trp (W) amino acid residue in S1 peptide 
(N-GFKLKGMARISCLPNGQWSNFPPKCIRECAMVSS-C) enabled the assessment 
of fluorescence change when S1 interacted with the hydrophobic region of LPS. Trp 
fluorescence scanning spectroscopy was used to study the hydrophobic interaction 
between S1 and LPS (Figure 3.29).  The penetration of S1 into the LPS aggregates  
was confirmed by determining the fluorescence emission spectra due to the Trp 
residue in S1 when in the presence of the LPS.  The addition of LPS to the peptide 
sample caused a blue shift of 4 nm in the emission peak, from 354 nm to 350 nm.  
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This blue shift indicates that the Trp residue was partitioned into a more hydrophobic 
environment, which would be expected if the Trp residue was positioned amongst the 
acyl chains of the LPS.  With LPS added, the fluorescence intensity increased, 
suggesting that the Trp residue was more sterically confined within the hydrophobic 





Figure  3.28 Determination of the stoichiometry of interaction between LPS and 
TMR-S1.  The concentration of fluorescent particles /complexes was measured for reaction 




Figure 3.29 Trp fluorescence scanning spectroscopy shows the excitation fluorescence 
spectrum of S1 in different concentrations of LPS.  The samples were all dissolved in 10 
mM phosphate buffer, pH 7.2.  The change in the spectra of the S1 peptide in 0 mM LPS 
(        ); 10 mM LPS (        ); 20 mM LPS (       ); 50 mM LPS (        ) and 
100? mM LPS (        ) were recorded. 
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3.4.6 Disruption of LPS aggregates by S1 peptide  
FITC labeled E.coli LPS and non-labeled S1 peptides were used in FCS analysis 
to study the effect of peptide on LPS aggregates. Figure 3.30A shows that the 
diffusion time, t DL,  (diffusion time of large particle) was dramatically  decreased in the 
presence of 10 mM of S1 peptide, indicating that the S1 interacted with and perturbed 
the large LPS aggregates to form smaller aggregates/complexes of S1-LPS. Actually 
like the detergent, Triton X-100, the S1 peptide interacted with FITC-LPS to decrease 
its t DL and exhibited the same activities for LPS aggregates (Figure 3.30A ).  
Pseudomonas LPS labeled with R18 (Octadecyl rhodamine B chloride) was also used 
in fluorescence correlation spectroscopy experiments (Li et al., 2004; Yu et al., 2005).  
In the absence of S1, large fluorescent micelles of R18-LPS were present like 
FITC-LPS (E. coli) aggregates.  However, the diffusion time, tDL, was dramatically 
decreased in the presence of 10 mM of S1 peptide, indicating that the S1 interacts 
with and perturbs the large LPS micelles. Thus, S1 peptide was shown to attain a 







Figure 3.30 Determination of the stoichiometry of LPS aggregates and S1 peptide 
interaction. (A) S1 peptides disrupted FITC-LPS (E.coli) aggregates. The FITC-LPS was 
held constant at 500 nM.  The concentrations of S1 peptide were 10 mM, respectively and 
the concentration of Triton X-100 is 0.2%. (B) S1 peptides disrupted R18-LPS (Pseudomonas)  
aggregates. The LPS was held constant at 100 nM.  The concentrations of S1 peptide were 
10 mM. All data points are averaged over 10 experiments. 
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3.4.7 S1 peptide competes against rFC from binding LPS 
We used a sensitive and precise rFC assay to examine the ability of the peptides 
to bind 50 EU/mL of LPS per mL. Figure 3.31 shows that S1 competes against rFC 
for LPS, and this competition was dosage-dependent. S1 peptide at 10 mM almost 
completely inhibited the rFC activity, suggesting that S1 peptide prevented LPS from 
binding to recombinant Factor C. However, the level of inhibition of binding of  
mixtures of peptides (S1 and S3) and rFC for the LPS neutraliz ation did not increase. 
when compared with the same concentrations of S1 or S3 peptides individually. 
 
3.4.8  The S1 peptide inhibits LPS-induced TNF-a production  
The ability of Sushi 1 peptide to inhibit TNF-a  production induced by endotoxin 
was tested. Like S3, the S1 peptide caused inhibition of the LPS-induced TNF-a 
production. However, the mixture of S1 and S3 peptides did not show cooperative  
inhibition ability compared with the same concentration of the individual S1 or S3 
peptides (Figure 3.32), suggesting that the potential models of the interaction between 
S1:LPS and S3:LPS are different and may not be additive.  
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Peptide Concentration (mM) 
Figure  3.31 Inhibition of the LPS-induced recombinant Factor C in the PyroGene assay.  
Binding of the Sushi peptides to LPS competitively inhibits the LPS-induced recombinant 
Factor C activity. Peptide concentration in “S1+S3 I” indicates total peptide concentration.e.g. 
1000 nM means 500 nM S1+500 nM S3. Peptide concentration in “S1+S3 II” means total 
peptide concentration.e.g. 1000 nM indicates 1000 nM S1+1000 nM S3.  
 
 
Figure 3.32   Sushi peptides inhibit the LPS -induced TNF-a  production. The LPS 
concentration is fixed at 10 ng/mL. THP-1 derived macrophage was activated by LPS and 
peptides together during 6 hours, and the production of TNF -a  was detected by anti-TNF-a 
ELISA. Peptide concentration in “S1+S3 I” means total peptide concentration.e.g. 1000 nM 
means 500 nM S1+500 nM S3. Peptide concentration in “S1+S3 II” indicates  total peptide 
concentration.e.g. 1000 nM indicates 1000 nM S1+1000 nM S3.  
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3.4.9 The toxicity of S1 peptides on human cells  
The potential toxicity of Sushi peptides to mammalian cells was tested by 
incubating with THP-1 cells and analyzing using MTS. At 100 mM, Sushi peptides 
showed minimal effect on cell permeabilization/cytotoxicity (Figure 3.33).  
Therefore, like S3, S1 could effectively inhibit the LPS-induced sepsis without being 





Figure 3.33 Sushi peptides show minimal toxicity to mammalian cells. THP -1 cells were 
incubated with Sushi peptides for 24 hours. The cell survival rate was detected by MTS assay.  
. 
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3.5 Electrostatic and hydrophobic forces contribute to the interaction between 
Sushi peptides and anionic phospholipids  
Previous works have focused on the effects of these peptides on LPS.  It has 
been shown that Sushi peptides bind LPS and disrupt LPS aggregates.  However, 
amongst the LPS molecules on the outer membrane of gram negative bacteria are 
phospholipids , which are also localized on the inner membrane (Figure 1.1).  This 
prompted us to investigate the interaction between Sushi peptides and phospholipids.  
Phospholipids are important constituents of both the bacterial and mammalian cell 
membranes.  But, the composition of phospholipids on the membrane of bacteria is 
rather different from that of mammalian cells).  The mammalian cell membrane 
comprises mainly phosphatidylcholine (~45% PC) phosphatidylethanolamine (~15% 
PE), phosphatidylserine (~5 % PS) and small amounts of other phospholipids, most of 
which are neutral at physiological pH.  In contrast, bacterial membranes such as that 
of Pseudomonas harbor substantial amounts of negatively charged phospholipids, 
such as phosphatidylglycerol (PG), besides neutral phospholipids, PE (Figure 1.4).   
Furthermore, it was discovered that there are some negatively charged 
phospholipids, which are similar in structure to lipid A of LPS (Lysko and Morse, 
1981).  Both lipid A and anionic phospholipids have negatively charged headgroups 
and lipid tails.  Thus, some anionic phospholipids, for example phosphatidylglycerol 
(PG), are thought to be LPS antagonists (Hashimoto et al., 2003; Mueller et al., 2005). 
PG and their analogue phospholipids, like PC (phosphatidylcholine), PE 
(phosphatidylethanolamine) and PS (phosphatidylserine), are different in their 
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headgroups and lipid tails, thus anionic phospholipids can be used to study the 
contribution of chemical forces from their different headgroups and lipid tails.  This 
prompted us to further investigate the interaction between the Sushi peptides and the 
different phospholipids and to determine the contribution of the chemical forces of the 
interaction between the Sushi peptides and LPS.  
3.5.1 S1 specifically binds anionic POPG and not zwitterionic POPC and POPE 
Here, we used a dot blot approach to examine whether S1 peptide can 
differentiate the different phospholipids.  Figure 3.34 shows that TMR-S1 
specifically binds to anionic POPG and POPS but not the zwitterionic phospholipids, 
POPC and POPE.  These binding assays indicate that the dissimilarity in specificity 
was probably attributable to the charge difference amongst POPC, POPE POPG and 
POPS (Table 2).   
Consistent with dot blot results, the FCS analysis showed that TMR-S1 has 
stronger affinity for POPS and POPG than for zwitterionic POPC and POPE in 
solution (Figure 3.35).  At the initial stage, TMR-S1 exis ts in a free form as the 
predominant fluorescent species.  During the course of the interaction, t DL increased, 
demonstrating that the percentage of the complex between TMR-S1: phospholipid 





Figure 3.34 S1 specifically binds POPG, POPS on PVDF membrane.  A 
peptide–phospholipid dot blot assay was carried out with the PVDF membrane strips spotted 
with phospholipids: (i) Aliquots of 5 mL of different phospholipids: POPC, POPE, POPG and 
POPS were dotted on the membrane; (ii) Specific interaction is observed between TMR-S1 
and POPG and POPS.  The lack of interaction between TMR and the phospholipids  further 





Figure 3.35 TMR-S1 specifically binds POPG, POPS but not POPC or POPE in solution. 
Determination of the tDL (the diffusion time of large particles in seconds) of TMR-S1 in 
different solutions of phospholipids shows that TMR-S1 interacts with POPG.  The control 
was phosphate buffer.  
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To quantify the interaction between the peptides and the phospholipids-on-matrix, 
we coated the phospholipids on a biacore chip activated with a hydrophobic surface.  
Realtime bio-interaction analysis measured as a surface plasmon resonance, SPR, of 
the binding between S1 and various phospholipids was carried out.  A set of 
sensorgrams of S1 interacting with different phospholipids was used to demonstrate 
the affinity (Figure 3.36).  The increasing association curves describe the initial 
binding of the peptide to the phospholipids immobilized on the HPA chip, and the 
decreasing curves relate to the dissociation in realtime.  This trend was consistently 
observed for the binding of peptides to pure vesicles containing 100% POPC, POPE 
or POPG.  The sensorgrams revealed that the SPR signal intensity, measured in 
response units (RU), increased as a function of the concentration of the peptide bound 
to the immobilized phospholipids.  This indicates that the amount of peptide bound 
to the lipid was related to the affinity of the peptide for the phospholipids-on-chip.  
This was thus consistent with the dot-blot result (Figure 3.35), which clearly 
demonstrated that S1 bound more strongly to the anionic POPG compared to the two 







Figure 3.36 S1 specifically binds POPG but not POPC or POPE on an HPA chip. (A) The 
sensorgrams depicting the realtime biointeraction between the S1 peptides and the 
immobilized phospholipids: POPC, POPE or POPG.  The realtime biointeraction analysis at 
the flow rate of 20 mL/min also indicated the preference of S1 for POPG. (B) Enlargement of 
the sensorgrams of POPC and POPE,  depicting the realtime biointeraction between the S1 
peptides and the immobilized phospholipids: POPC and POPE.    
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3.5.2 Hydrophobic interaction contribute s significantly to the binding 
specificity of S1  to POPG  
We use Trp fluorescence scanning spectroscopy to study the hydrophobic 
interaction between S1 and phospholipids.  The Trp residue in S1 elicited a change 
in fluorescence.  The penetration of S1 into the phospholipid vesicles was confirmed 
by determining the fluorescence emission spectra due to the Trp residue in S1 when in 
the presence of the phospholipids.  The addition of anionic phospholipids, 100% 
POPG, 100% POPS or POPE:POPG mixture (1:1) to the peptide sample caused a blue 
shift of 4 nm in the emission peak, from 354 nm to 350 nm (Figure 3.37).  This blue 
shift indicated that the Trp residue partitioned into a more hydrophobic environment, 
which would be expected if the Trp residue was positioned amongst the acyl chains of 
the phospholipid.  In POPG, the fluorescence intensity increased, suggesting that the 
Trp residue in S1 was more sterically confined, while the fluorescence spectrum  of S1 
in POPC indicated that the local environment of Trp was kept in an original state and 
there was no interaction between S1 and zwitterionic lipids like POPC. 
To determine the extent to which S1 was sequestered in the hydrophobic core of 
the vesicle, a fluorescence quenching experiment was performed using acrylamide.  
This study was based on the premise that the hydrophobic core residue, Trp, in S1 is 
involved in hydrophobic interactions with the phospholipids, and that the fluorescence 
intensity of Trp is protected by phospholipids from acrylamide quenching.  The Fi/F0 
was calculated from the plots between 0 to 0.5 M acrylamide.  At 0.2 M acrylamide, 
the Fi/F0 of S1 was 25.7%, while in the presence of POPG, the Fi/F 0 increased to 
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44.4%. In the presence of POPE:POPG, the Fi/F0 was 37.1% (Table 5).  These 
values confirm that when the peptide is free in solution, it is much more accessible to 
the quencher (acrylamide) than in the presence of the anionic POPG vesicles.  Since 
the phospholipids confer protection of the Trp residues from the water-soluble 
acrylamide, it confirms that the S1 peptide was partially buried in the hydrophobic 







Figure 3.37 Hydrophobic interaction confers binding specificity of S1 peptide for anionic 
phospholipids, POPS and POPG.  (A) Trp fluorescence scanning spectroscopy shows the 
excitation fluorescence spectrum of S1 in individual phospholipids.  The blue shift in the 
presence of POPG and POPS indicates that the environment of Trp in S1 has altered from a 
hydrophilic to a hydrophobic state.  (B) Trp fluorescence scanning spectroscopy of S1 in 
representative combinations of POPE:POPG (according to bacterial membrane phospholipid 
composition) and POPC:POPE:POPS (according to mammalian membrane phospholipid 
composition).  The blue shift in the presence of POPG indicates that the environment of Trp 
in S1 has altered from a hydrophilic to a hydrophobic state. 
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Table 5. Fi/F0* determined from Trp fluorescence quenching experiments 
Acrylamide 
[M] 
F i/F0 [%] 
(S1 in water) 
Fi/F0 [%] 
(S1 in POP G) 
F i/F0 [%] 
(S1 in POPE:POPG) 
0 100±3.0 100±1.6 100±2.6 
0.05 78.5±3.2 80.3±1.7 73.7±2.6 
0.1 56.3±3.0 65.1±1.0 56.9±1.4 
0.2 25.7±1.5 44.4±1.7 37.1±1.0 
0.5 5.60±0.4 15.5±1.6 12.1±1.1 
 
*F i is the fluorescence peak intensity of Trp with acrylamide and F0 is the fluorescence peak 
intensity without acrylamide.  
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Conformational change could occur to the peptides because of their 
hydrophobic interactions with the anionic phospholipid vesicles.  Therefore, we used 
CD measurements to examine the secondary structure of these peptides in the 
presence and absence of the phospholipids .  In aqueous solution, in the absence of 
phospholipids , S1 adopted a random coil conformation as shown by the single 
minimum at 200 nm (Figure 3.38A).  With vesicles constructed using 100% POPC, 
POPE, POPG or POPS, only the anionic POPG and POPS (1:1) vesicles could induce 
conformational change in S1.  In the presence of a mixture of anionic phospholipids 
(POPE:POPG at 1:1), the S1 peptide also exhibited a spectrum characteristic of an 
a-helix demonstrating a pair of minima at 208 nm and 225 nm (Figure 3.38B). This is 
consistent with the CD spectrum of the a -helical antimicrobial peptide, magainin 











Figure 3.38 The CD spectra of S1 peptide in the presence of individual phospholipid 
solutions. (A) The conformation shift in the presence of POPG and POPS indicates that S1 
has specificity for anionic phospholipids. (B) The CD spectra of S1 in POPC:POPE:POPS 






3.5.3 The unsaturated nature of POPG enhances its interaction with S1  
To this point, I have demonstrated that both the headgroup and lipid tails of 
POPG were indispensable for interaction with the S1 peptide.  Incidentally, POPG is 
unsaturated and the fluidity of biological membranes is attributable to its unsaturation.  
Thus, we compared the interactions between S1 peptide and unsaturated POPG with 
that of saturated DPPG (Figure 3.39).  Comparatively, the intensity of Trp-mediated 
fluorescence change was higher in POPG than in DPPG (Figure 3.40).   
Furthermore, S1 was more readily transformed into an a -helix in the presence of 
POPG rather than in DPPG (Figure 3.41).  The results suggest that S1 more easily 
inserts into the lipid tail of POPG than that of DPPG.  Being unsaturated, POPG 
confers greater fluidity to the anionic lipid layer.  
Since temperature also affects the fluidity of a lipid layer, we monitored the 
realtime interaction between S1 and POPG at different temperatures (Figure 3.42).  
The results showed that S1 binds stronger at 37oC than 25oC, suggesting that the 
unsaturated nature of POPG is prominent at 37oC and this confers increased fluidity to 









Figure 3.39 The molecular structure of POPG and DPPG. The lipid tail of POPG 
(palmitoyl-oleoyl-phosphatidylglycero) is unsaturated, while the lipid tail of DPPG 






Figure 3.40 Trp fluorescence scanning spectroscopy shows the excitation fluorescence 






Figure  3.41 The CD spectra of S1 peptide in the presence of the saturated and 





Figure 3.42 The sensorgrams depicting the realtime biointeraction between the 
immobilized POPG and S1 at 25 and 37oC, at the flow rate of 100 mL/min. 
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3.5.4 S3 also specifically interacts with anionic phospholipids   
To test the affinity of S3 for anionic phospholipids, a set of sensorgrams 
showing the profiles of its interaction with different concentrations of phospholipids  
were analyzed.  Figure 3.43 revealed that the signal intensity measured in response 
unit (RU) increased as a function of the S3 peptide bound to the anionic phospholipids 
compared with zwitteronic phospholipids.  Thus, this indicates that S3 also exhibited 
a consistent preference for POPG.  
Unlike S1 (Figure 3.38) and magainin (Tachi et al., 2002) which are random in 
aqueous environment, S3 exhibited a mixture of a-helix, b-strand and random coil 
(Figure 3.44).  S3 remained unchanged in POPC and POPE, but the content of 
a-helicity increased somewhat in the presence of POPG, giving a mixture of a-helix 






Figure 3.43 The sensorgrams depicting the realtime biointeraction between the 




Figure 3.44 The CD spectra of S3 peptide in the presence of individual phospholipid 
solutions. 
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3.5.5 S1 and S3 disrupt POPG vesicles  
To test the biological significance of the specifc interaction between the Sushi 
peptides and POPG, I constructed two kinds of labeled POPG vesicles, REV and RLV, 
to interact with different concentrations of the peptides.  0.2% Triton X-100 was 
used to disrupt the phospholipid vesicles as the positive control. When incubated with 
0.1 and 1 mM S1, the t DL of REV and RLV did not decrease (Figure 3.45 A and B), 
indicating that the vesicles remained intact at these concentrations of peptides.  In 
contrast, when incubated with 10 mM S1, the tDL of REV decreased dramatically 
(Figure 3.45C).  This indicates the disruption of the POPG-containing REV, resulting 
in the release of small fluorescent particles such as free Rhodamine-6G/Rhodaime-PE 
molecules.  In comparison, when RLV was incubated with 10 mM S1, the t DL 
remained unchanged.  In contrast, at 10 mM, S3 decreased the tDL of both the REV 
and RLV (Figure 3.45C), demonstrating that S3 can disrupt POPG vesicles completely.  
Thus, at the same concentration, the S1 and S3 peptides elicited different effects on 
POPG bilayer vesicles. The different manner of interaction with POPG of S1 and S3 
might have been due to the different inherent secondary structures of the peptides 





Figure 3.45 S1 and S3 show different modes of disruption of POPG vesicles. 
Determination of the stoichiometry of interaction between REV POPG vesicles and Sushi 
peptides, ?tDL, the diffusion time of large particles, (s, seconds): REV, RLV incubated with 
different concentrations of Sushi peptides: (A) 0.1 mM, (B) 1 ?mM, (C) ?10?mM.  As an internal 




Here, we studied the mechanisms of the interaction between S1 and S3 and the 
anionic phospholipids, POPG, in comparison with zwitteronic phospholipids, POPC 
and POPE.  S1 exhibited specificity against POPG, suggesting its preference for 
anionic phospholipids, regardless of whether the phospholipids formed vesicles in 
solution or were present as a monolayer on a solid surface.  This specificity of the 
interaction of the Sushi peptides with POPG was possibly a consequence of the 
electrostatic and hydrophobic forces.  Furthermore, we observed that the unsaturated 
nature of POPG confer red fluidity to the lipid layer and enhances anionic 
phospholipids to bind with the peptide.  Furthermore, during the  interaction with 
POPG, the S1 peptide transitioned from random coil to a-helix, which was different 
from the effect of another Sushi peptide, S3.   Considering that POPG and LPS are 
both anionic lipids, the results could be helpful to design and develop a new 
generation of LPS-neutralizing peptide and to offer some clues on the specific 
function of Factor C, an LPS-biosensor. 
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Chapter 1 presented the role of LPS in septic shock as a result of the  systemic 
infection, where LPS is released from the bacterial cell membrane into the blood 
stream and is captured by the LPS-binding protein (LBP) in the host (Schumann et al., 
1990).  The LBP-LPS complex is subsequently transferred to the host immune cells  
and interacts with CD14 (Wright et al., 1990) and Toll-like receptor 4, TLR4 (Yang et 
al., 2000).  Then, LPS-induced signal turns on protein kinases such as p38 (Sweet 
and Hume, 1996), and transcription factors, which in turn activates gene transcription 
of numerous pro-inflammatory cytokines, tissue factor, adhesion molecules and 
inducible nitric oxide synthetase.  Amongst the pro-inflammatory cytokines, TNF-a 
plays a critical role in the inflammatory response and is often regarded as a hallmark 
of LPS-induced inflammation (Tang et al., 2005) . Currently, studies around the world 
have focused on the intervention of LPS-induced inflammatory response with 
potential LPS-neutralizing drugs to bind LPS and to inactivate the LPS signaling 
pathway.  Numerous proteins and peptides have evolved for the purpose of binding 
and neutralizing LPS from insects and mammals (Arana Mde et al., 2003; Elsbach 
and Weiss, 1998; Hirata et al., 1995; Lepper et al., 2005; Scott et al., 2000).  
Amongst these is Factor C, an LPS sensor protein in the horseshoe crab. Although 
many reports have documented the LPS-activated Factor C initiation of the 
coagulation cascade (Ding and Ho, 2001; Iwanaga et al., 1994) , no effort has to date  
been made to exploit the high affinity of Factor C for trace amounts of LPS for 
endotoxin-neutralization applications.  Nevertheless, owing to its extreme sensitivity 
to endotoxin, Factor C, a serine protease, has played an important biotechnological 
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role in pyrogen detection in the pharmaceutical and biomedical industries.  
Previously, many earlier attempts to express Factor C in heterologous hosts faced 
limited succes s (Roopashree et al., 1995) .  The reason was largely due to its highly 
complex mosaic structure.  Using a cross-host secretary signal (Tan et al., 2002), 
which leads to the secretion of various recombinant proteins in both prokaryotic and 
eukaryotic systems, our lab has recently produced full-length and biologically 
functional domains of Factor C that bind LPS (Wang et al., 2002).  Thus, it is 
possible that recombinant Factor C protein and its derived Sushi peptides can be 
applied to the neutralization of LPS in vivo. 
 
4.1 The recombinant Factor C (rFC) shows endotoxin neutralization cap ability 
Here, we used recombinant Factor C (Figure 3.1), shown to be similar to the 
native Factor C purified from the blood of horseshoe crab (Ding and Ho, 2001; Ding 
et al., 1993; Iwanaga et al., 1994)  to compete against the LBP peptide for LPS.  Our 
data clearly demonstrated that LBP peptide can inhibit the LPS-induced rFC enzyme 
activity (PyroGene assay). The Factor C was found to bind lipid A of LPS (Nakamura 
et al., 1988).  LBP peptide also binds the lipid A motif of LPS (Pristovsek et al., 
2005).  Thus, rFC and LBP peptide compete with each other for the same bioactive 
chemical moiety of LPS.  We envisage that when rFC occupies the lipid A moiety of 
the LPS molecule, it deprives the LBP of its binding site on LPS.  Factor C is 
reported to bind LPS with very high affinity of 7.56 x 10-10 M (Ariki et al., 2004). 
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Thus, Factor C can prevent LPS from binding other LPS effectors like LBP peptide. 
In fact, increasing doses of rFC were able to dissociate LBP peptide from LPS (Figure 
3.2), suggesting that rFC can possibly reduce the detrimental effects of LBP-LPS 
complex-driven inflammation. During gram-negative infection, LPS activation of the 
host cells leads to multiple organ failure and septic shock. These adverse effects are 
dependent on the generation of endogenous mediators. A multitude of mediators have 
been implicated, including arachidonic acid metabolites, and cytokines such as TNF-a. 
In view of the endotoxin-neutralization capability of rFC, it could be developed to 
prevent LPS from activating the host cell. Here, we investigated the hallmarks of LPS 
signaling pathway in the mammalian host.  Our results demonstrated that the 
phosphorylation of p38 in the LPS signaling pathway was reduced by rFC (Figure  
3.3). We showed that the LPS-induced phosphorylation of p38 could be inhibited by 
rFC to ameliorate the production of TNF-a (Figure 3.4). This intervention could be 
responsible for rFC-mediated block in LPS signaling pathway in the mammalian cell.  
Furthermore, we showed that rFC is non-toxic to human monocytes and HeLa cells 
(Figure 3.5).  
In view of the above observations, rFC could be a potential LPS-neutralizing 
antidote. It is possible to design and develop efficacious LPS-neutralizing drugs from 
the Factor C molecule. The high affinity LPS-binding domains of rFC could also be 
developed into candidate tools to remove endotoxin as contamina nt in biomedical 
fluids and implantable devices.  
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4.2 The recombinant S3 (rS3) peptide exhibits anti-LPS effects but is less 
efficacious than chemically synthesized peptides 
Since rFC has been shown to compete efficaciously against LPS-effectors for 
LPS, and is capable of suppressing LPS-induced signa ling, it was imperative for us to 
examine the possibility of using Factor C derived Sushi peptides for the purpose of 
LPS-neutralization. In previous studies, the two 34-mer synthetic peptides, S1 and S3, 
that span the 171–204 and 268–301 amino acid residues of Factor C were shown to 
interact with LPS (Gene Bank Accession Number: S77063) (Tan et al., 2000b) .  Both 
peptides bind LPS and can compete with the recombinant Factor C for LPS binding. 
Thus, the S1 and S3 peptides are potential endotoxin antagonists.  The application 
value of these two peptides would be boosted if they could be obtained by 
cost-effective and large-scale methods such as recombinant expression in prokaryotic 
systems.  However, expression of small peptides tends to encounter technical 
problems (Latham, 1999; Le and Trotta, 1991) .  It is reported that some of these 
problems could resolved by multimerization of the small peptide followed by in vitro  
digestion to restore their monomeric forms (Mauro and Pazirandeh, 2000). In our lab, 
we had successfully cloned the tandem repeats of S3 gene into the modified vector 
pET22b-S3-4mer (Figure 3.6) (Li et al., 2003).  Thus, the recombinant S3 peptide  
could be produced by purification and digestion of the multimers (Figure 3.9 & 3.10).   
Tricine electrophoresis showed that rS3 forms dimers with intermolecular 
disulfide bonds (Figure 3.11), which stabilize the secondary structure of rS3 (Figure 
3.12).  Although recombinant Sushi peptides was successfully engineered and 
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purified, it showed anti-LPS activity which was comparatively lower than that of the 
chemically synthesized counterpart peptide show ing that the recombinant S3 peptide 
was less efficacious. 
Nevertheless, our work suggested that there are two major forces mediating the 
interaction between LPS and the Sushi peptides (Figure 3.14).  The positive charge 
on the peptides forms an electrostatic attraction with the negatively charged phosphate 
head groups of the LPS.  The other is the hydrophobic interaction between them.  
The D-P linker added into the rS3 monomer introduced the negatively charged amino 
acid, Asp, into the S3 sequence, thus decreases the electrostatic forces between the 
peptide and LPS.  Furthermore, in the preparation of the rS3 monomer, the rS3-4mer 
peptides had been digested in formic acid to release the rS3 monomer, and some other 
amino acids could have been modified into methyacrylated forms by formic acid as 
evidenced by MS result (Figure 3.11). In this regard, it is also highly possible that this 
modification may include the structural change of rS3 which was responsible for the 
observed loss of activity.  Thus, the primary sequence of S3 peptide had been modified 
which may decrease its ability to interact with LPS. Since rS3 peptide was shown to 
be less active, the chemically synthesized S3 peptides were studied for the remaining 
parts of the thesis. 
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4.3  The structure -activity relationship of Sushi peptide s  
4.3.1 The S3 peptide is functionally active as a dimer 
It has been reported that for some peptides, multimers are more active than 
their corresponding monomers (Lai et al., 2002; Situ et al., 2003; Wu et al., 2003).  
Thus, cysteine can affect the LPS binding ability of S3 peptides.  Since chemically 
synthesized S3 peptide also contains a single cysteine, it is conceivable that in 
solution, S3 exists in two forms: the monomer ic peptide without a disulfide bond and 
the dimeric peptide linked by an intermolecular disulfide bond.  In order to gain a 
global perspective on the tolerance of cysteine residues in S3 to amino acid 
substitutions, a mutant peptide named S3-C27S (where cysteine 27 was changed to 
serine, C27S), was synthesized (Figure 3.15) and the structure-activity relationship 
was analyzed.  The S3-C27S is deemed to remain a monomer because there could be 
no intermolecular disulfide bond formation between S3-C27S peptides.   The effects 
of the S–S bridged S3, and the conformationally altered mutant, S3-C27S, and their 
biological activities were investigated here.  
According to the secondary structures of peptides , small peptides are 
commonly classified into four groups: Group I comprises linear peptides with 
a-helical structure, for example, magainin (Maloy and Kari, 1995) and alamethicin 
(Bak et al., 2001).  Group II comprises peptides containing b-sheet structure and one  
or more disulfide (S–S) bonds, for example, bactenecin (Romeo et al., 1988) and 
lactoferricin (Hwang et al., 1998).  Group III comprises cyclic peptides  like V4, 
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(Frecer et al., 2000a,b), nisin (Van de Ven et al., 1991) and RTD-1 (Trabi et al., 2001) . 
They were predicted to form amphipathic  ß-hairpin-like structures when they bind to 
LPS or LA. Group IV encompasses other peptides, for example, trichogin G IV 
(Toniolo et al., 1994) , which cannot be included into the three former groups .  Our 
results demonstrate that the S3 peptides have a propensity to dimerise via  an 
intermolecular disulfide bond (Figure 3.16), which is probably responsible for its high 
affinity for LPS. Thus, we classified S3 into group II peptides, while S1 peptide is 
classified into group I peptides.  It has been shown that in an aqueous environment, 
many short peptides have no defined structure.  For example, typical amphipathic 
a-helical peptides such as magainins and cecropins are unstructured in aqueous 
solution.  In contrast, small b-sheet peptides, such as tachyplesin, protegrin  and 
lactoferricin B, are already in a more or  less de fined amphipathic sheet structure in 
aqueous solution (Epand and Vogel, 1999) .  The disulfide bonds stabilize the 
secondary structure of the S3 dimer (Figure 3.17 & 4.1 A), in agreement with the 
report of Tam et al. (2002).  Presum ably, this structure is important for the 
interaction between S3 dimer and LPS, during which the S3 dimer forms a b-sheet 
structure to provide better shielding of the hydrophobic acyl chains of LPS (Figure 
4.1B).  This may explain why the  S3 dimer displays  a stronger LPS-neutralizing  
capability than its monomeric counterpart (Figure 3.22 &3.23).  This possibility was  
clearly demonstrated and corroborated by the S3-C27S mutant, which as a monomer 
exhibited a complete structural changeover with a marked decrease in binding and a 








Figure 4.1 S3 functions as a dimmer. (A) Dimerisation of S3 peptide occurs through an 
intermolecular disulfide bond. (B) S3 dimer interacts with lipid A of LPS molecules. 
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The higher affinity of S3 dimer for LPS was confirmed by a panel of 
experiments including SPR and FCS.  Consistently, it was evident from all the 
experimental approaches that the S3 dimer was stabilized by intermolecular disulfide 
bonding (Figure 3. 18), and it exhibited a higher affinity for LPS (Figure  3.19).  
Using FCS, we compared the activity of the peptides in solution.  During titrations of 
TMR-S3 with LPS, the dimer consistently showed stronger binding than the monomer 
as indicated by longer diffusion time (t DL) of peptides bound to LPS aggregates at all 
concentrations.  Furthermore, the FITC-LPS of FCS system revealed a decrease in 
tDL with an accompanying increase in the particle number , NF, indicating that S3 
dimers rather than their monomeric counterparts had disrupted the  LPS aggregates  
(Figure 3.21).   
 
4.3.2 S3 dimer disrupts LPS aggregates via a “detergent-like” mechanism  
By FCS analysis, S3 dimer and Triton X-100 seemed to exhibit similar specific 
activities for LPS aggregates (Figure 3.21).  S3 peptide was shown to attain a 
“detergent-like” activity after reaching a threshold concentration, consistent with the  
report by Bechinger for other peptides (Bechinger 1997). Triton X-100 can be 
employed in two-phase LPS extraction.  Above the critical micellar concentration of 
Triton X-100, LPS aggregates are disrupted by non-polar interactions between the 
alkyl chains of LPS and Triton X-100 and are consequently separated from the water 
phase (Bordie r, 1981).  In a similar manner, it is possible that at high concentrations, 
 143 
S3 dimer binds the acyl chains of LPS, thereby disrupting the critical force that 
maintains  the stability of LPS aggregates.   
Besides hydrophobic interactions, it is important to consider the electrostatic 
forces between the peptide and LPS in aqueous solutions (Ding et al., 2001; Frecer et 
al., 2000a; Frecer et al., 2000b).  Near the N-terminus of S3 there are several 
positively charged amino acids such as lysine residues, whereas the C-terminus of S3 
is more hydrophobic  (Figure 3.15). Conversely the diphosphoryl head groups on the 
LPS confer a net negative charge while its acyl chains are hydrophobic.  Therefore, 
S3 binds LPS through a preliminary interaction between the cationic amino acids at 
the N-terminus of S3 and the diphosphoryl head groups of LPS, followed by 
stabilization of the resulting molecular complex through a hydrophobic interaction via 
the C-terminus of S3 and the fatty acyl chains of LPS.  This is in agreement with our 
previous observations that mutations of the N-terminus to introduce two extra lysine 
residues into S3 (S3d) resulted in an increase in LPS neutralizing activity (Tan et al., 
2000b).  It was reported that the aggregated form of LPS is biologically more active 
than the free LPS molecules (Mueller et al., 2004). Thus, disruption of the LPS 
aggregates by S3 dimer peptides may be responsible for the LPS neutralization. The 
dimeric form of S3 is more stable with LPS, allowing the prolonged and persistent 
interaction with LPS and disruption of the LPS aggregates (Figure 3.21). (Bechinger, 
1997) 
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4.3.3 S1 peptide interacts with LPS as a monomer 
In view of the presence of another LPS-binding Sushi domain (Sushi 1) of the 
Factor C molecule, we sought to examine the mechanism of the interaction between 
the chemically synthesized S1 peptide and LPS.  Since S1 peptide contains three 
cysteine residues (Figure 3.24), it could possibly form multimers.  Furthermore, the 
structure of S1 peptide could be stabilized by the intermolecular disulfide bond.  
Thus, the structure -activity relationship of S1 was studied using some biophysical 
methods. Since LPS exists in aggregates in solution (Bordier, 1981) , the influence of 
S1 peptide on LPS aggregates was evaluated by FCS, and the S1 peptide-mediated 
inhibition of LPS-induced rFC activity was measured.  Our results show that under 
the physiological conditions, S1 peptide was monomeric and 4 kDa in mass (Figure 
3.25). S1 adopted a random structure in aqueous solution (Figure 3.26) . This is 
similar to the results reported for maganin and other monomeric peptides (Chan et al., 
2004; Mozsolits et al., 2001; Pierre et al., 2000). As compare d to S3 (pI 7.27), S1 has 
pI of 9.63.  The higher net positive charge on S1 might cause charge repulsion of 
other monomers and hence attribute to its lack of intermolecular disulfide bond 
formation. 
 
4.3.4 S1 peptide interacts with LPS via a hydrophobic interaction 
The Trp fluorescence scanning spectroscopy experiment (Brandenburg et al., 
2005; Zhang et al., 2000)  revealed that the microenvironment of the S1 peptide was 
 145 
transformed from a hydrophilic to a more hydrophobic state, in the presence of the 
anionic LPS (Li et al., 2006c).   The addition of LPS to the peptide sample caused a 
blue shift in the emission peak, from 354 nm to 350 nm (Figure 3.29), which 
indicated that the Trp residue partitioned into a more hydrophobic environment.  The 
fluorescence intensity increased, suggesting that the Trp residue was more sterically 
confined. Based on the LPS structure, only the fatty acyl chain of lipid A could offer a 
more hydrophobic environment.  It suggests that the Trp residue of S1 peptide was 
partitioned into the hydrophobic acyl chains of lipid A in LPS.  Since lipid A is the 
bioactive part of LPS, the binding of S1 peptide with lipid A could decrease the 
interaction of LPS with other LPS binding sensors in the host and therefore reduce the 
endoxicity of LPS (Li et al., 2006b).   
  
4.3.5 S1 peptide disrupts LPS aggregates like S3 
Hydrophobic interaction contributes significantly to the binding between the S1 
and bacterial LPS.  Here, firstly, we demonstrate that the hydrophobic  interaction is 
significant between non-labeled LPS aggregates and S1 peptide in solution (Figure 
3.29).  The observation of the heterogeneity of  LPS aggregates in solution has 
prompted us to investigate the change in LPS aggregates or vesicles in the presence of 
S1.  To this end,  FITC-LPS was used in FCS experiments (Li et al., 2004; Yu et al., 
2005).  However, the diffusion time of the large LPS aggregates, t DL, was 
dramatically decreased in the presence of 10 mM of S1 peptide, indicating that S1 
interacts with and perturbs the large LPS aggregates.  Like the Triton X-100, the S1 
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peptide interacted with FITC-LPS to decrease its t DL and exhibited the same specific 
activities for LPS aggregates (Figure 3. 30).  Thus, S1 peptide was shown to attain a 
“detergent-like” activity, a property which is also exhibited by S3 peptide. It is 
possible that during interaction, both of S1 and S3 could bind the acyl chain of lipid A, 
thus disrupting the critical force, which maintains the stability of the LPS aggregates.  
The gram negative bacteria display and release a variety of different LPS formats 
from their outer membranes.  Here we have shown that the LPS aggregates were 
disrupted by Sushi peptides, which may be related to LPS neutralization. 
 
4.3.6 S1 and S3 independently exert antagonistic activities against LPS 
In our work, suppression of LPS-induced TNF-a secretion from THP-1 by 100 
mM of S1 and S3 peptides revealed that the Sushi peptides can exert 50% inhibition 
of LPS-induced TNF-a production (Figure 3.32). However, the full length 
recombinant Factor C (rFC), from which the Sushi peptides are derived, was found to 
be more efficacious than S1 or S3 (Figure 3.4). Even when S1 and S3 were 
co-incubated with LPS, there was no cooperative activity unlike what was observed 
for rFC (Tan et al., 2000b). Such cooperativity found between Sushi 1 and 3 domains 
in rFC leads to rapid amplification of the activation of the Factor C proteins induced 
by LPS, thus explaining the extreme sensitivity of rFC for trace levels of LPS in 
solution. Furthermore, the Factor C is a large protein and it contains other domains 
besides Sushi 1 and 3 domains. The other domains might also enhance the interaction 
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Factor C w ith LPS. Thus, future attempts may be made to increase LPS binding 
affinities of S1 and S3 peptides by producing hybrid multimers of S1 and S3 peptides. 
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4.4  The selectivity o f Sushi peptides for LPS and Anionic phospholipids   
Some anionic phospholipids, for example phosphatidylglycerol (PG), are thought 
to be LPS-antagonists (Hashimoto et al., 2003; Mueller et al., 2004).  This prompted 
us to investigate further the interaction between peptides and anionic phospholipids.  
Furthermore, Sushi peptides have been demonstrated to bind and kill an opportunistic 
gram negative bacterium, Pseudomonas aeruginosa (Yau et al., 2001) , while 
exhibiting minimal cytotoxicity to human monocytes, THP-1 (Tan et al., 2000b). Thus, 
here, we used zwitteronic phospholipids as a control for anionic phospholipids. 
Previous reports on the investigation of the interaction of bacterial phospholipids and 
other peptides, are limited to the headgroups of bacterial phospholipids (Blazyk et al., 
2001; Papo and Shai, 2003; Tachi et al., 2002) .  In this work, we investigated not 
only the effects of the headgroups and the lipid tails, but also the effect of the 
unsaturated nature of POPG on their interaction with LPS-binding Sushi peptides, (S1 
and S3).  We examined the detailed molecular mechanisms underlying the 
contribution of the interaction of anionic phospholipids w ith Sushi peptides.  Here, 
we designed experiments to investigate the specificity and selectivity of the Sushi 
peptides towards anionic phospholipids.  In this work, we used POPG from the 
bacterial membrane , POPS from the mammalian cell membrane, and employed POPC 
and POPE from the mammalian cell membrane as negative control (Fernandez et al., 
2002; Mani et al., 2004; Murzyn et al., 2005).  Since it has been reported that 
membrane phospholipids like POPC and POPG can form unilamellar vesicles, while 
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POPE forms hexagonal vesicles (McIntosh, 1996), we employed various biochemical 
and biophysical methods using different forms of the phospholipids (both in solution 
and solid phase) in order to provide compelling evidence for the mechanism of 
interaction between the peptides and the phospholipids. 
 
4.4.1 Electrostatic forces contribute to the interaction between Sushi peptides 
and anionic phospholipids 
By a series of analyses, we demonstrated that S1 and S3 peptides interact more 
strongly with anionic POPG and POPS than zwitterionic POPC and POPE (Figure 
3.34-3.36 & Figure 3.43).  These results suggested that the biochemical properties of 
phospholipid play a crucial role in influencing and specifying the selectivity of the 
peptide.  The headgroup of POPG and POPS conferred anionicity to the molecules  
(Table 2).  This electrostatic difference contributed to the specificity of the Sushi 
peptides for LPS, which is also an anionic lipid.  Thus, the initial electrostatic 
interaction determined the specificity of the Sushi peptides for the bacterial LPS.  
Charge-charge interac tions between the cationic peptides and the anionic LPS were 
deemed to be the most critical binding force, explaining why the increase in the net 
positive charge of the peptides could enhance its binding to anionic lipids (Hong et al., 
2001; Tam et al., 2002) .  This possibility is corroborated by the work of Tan et al. 
(2000b), which found that mutations of the N-terminus by introduc ing two extra 
lysine residues into Sushi peptides resulted in an increase in LPS-neutralizing activity.  
In concordance, our present results suggest that the charge interaction is responsible 
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for the selective binding between the peptides and the bacterial LPS (Li et al., 2006c).  
Moreover, this electrostatic difference between the phospholipids accounts partly for 
the charge difference between the mammalian and the gram negative bacterial cell 
membranes, ultimately contributing to the specificity of the antimicrobial peptides, 
which preferentially bind to the exposed anionic surface of bacterial membranes, but 
not to the zwitterionic amphiphiles present in the extracellular monolayer of 
mammalian plasma membranes.  This could spare the mammalian host cells from 
any undesired peptide-induced injury.  Thus, the initial electrostatic interaction 
determines the specificity of the Sushi peptides for the bacterial membrane (Yau et al., 
2001). 
 
4.4.2 Hydrophobic  forces contribute to the interaction between Sushi peptides 
and anionic phospholipids 
Hydrophobic  forces contribute significantly to the binding interaction between 
the peptides and bacterial LPS (Brandenburg et al., 2005; Zhang et al., 2000) .  The 
Trp fluorescence scanning spectroscopy experiment revealed that during interaction 
with LPS or POPG (Figure 3.37) ,  the microenvironment of the S1 peptide is 
transformed from a hydrophilic to a more hydrophobic state, thus engaging the 
hydrophobic region of the peptide into an interactive bond with the acyl chains of the 
anionic lipids (Figure 4.2) (Li et al., 2006a).  Other studies by Bechinger (1997) and 
Matsuzaki et al. (1996) on cationic peptides, using NMR, Raman and fluorescence 
measurements, have indicated that initially, cationic amphipathic peptides would bind 
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parallel to the lipid layer.  Therefore, it may be envisaged that owing to the 
simultaneous electrostatic and hydrophobic forces, the binding of Sushi peptides with 
anionic lipids is highly salt-tolerant (Ding et al., 2001; Yau et al., 2001) .  In a high 
salt environment, when the electrostatic interaction is weakened, the hydrophobic 
interaction becomes the dominant force that maintains the affinity of the Sushi 
peptides for the anionic lipids.  The present study confirms that hydrophobic 
interaction between Sushi peptides and LPS is indispensable.  (Bechinger, 1997; 





Figure 4.2 The mechanism underlying the selective interaction between S1 and POPG 
layer.? S1 peptide specifically binds POPG via (I) electrostatic interactions between the 
positively charged amino acid residues near its N-terminus and the negatively charged 
bisphosphate headgroups of the POPG and (II) hydrophobic interactions between the 
hydrophobic region of S1 and the acyl chains of POPG. S1 forms an ?a-helical structure to 
insert into the POPG layer, thus, the Trp residue is probably protected by the lipid tail of 
POPG.  The N-terminal region of S1 is represented blue and C-terminus is annotated in 




4.4.3 Unsaturation of the lipid tails enhances the penetration of the Sushi 
peptides into the phospholipid vesicles 
My data also show that the unsaturated state of the lipid tail of POPG probably 
enhances the interaction between the peptide and POPG (Figure 3.40 & 3.41), which 
suggests that the unsaturated nature of the bacterial phospholipid confers fluidity to 
the vesicle , and possibly augments the insertion of such a peptide into the bilayer of 
vesicle  (Li et al., 2006a; Li et al., 2006c). The finding is consistent with the report of 
Pande et al. (2005).  This finding was also supported by assessing the effects of 
different temperatures on the realtime binding of S1 to POPG, which showed that at 
37 oC where the unsaturated membrane environment is anticipated to be more fluid 
than at 25 oC (Figure 3.42) , S1 binds more readily to the lipid.  This observation 
should be taken into consideration and exploited for future design and development of 
novel LPS-neutralizing drug peptides, to facilitate greater specificity and penetration 
of the peptides for the anionic unsaturated LPS and the membrane bilayer of the Gram 
negative bacteria. (Pande et al., 2005)  
 
4.4.4 The inherent difference in the S1 & S3 peptides sequence influence their 
modes of anti-LPS action 
Sushi peptides exhibit specificity against POPG, suggesting its preference for 
anionic phospholipids, regardless of whether the phospholipids form vesicles in 
solution or monolayer on a solid surface.  This specificity of the Sushi peptides 
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binding to POPG was a consequence of the electrostatic and hydrophobic forces.  
Furthermore, the unsaturated nature of POPG confers fluidity to the lipid layer and 
enhances the ability of anionic phospholipids to bind with peptide.  However, as 
shown by FCS experiments, S1 apparently acts differently from S3 at the same 
concentrations (Figure 3. 45).  This difference in the action between S1 and S3 is 
probably attributable to the inherent difference in the conformation of the two 
peptides whilst under the influence of the anionic phospholipid environment: the S1 
peptide transitioned from random to a-helical coil, in contrast to S3 that assumed a 
more modest change in conformation (Figure 3.38 & 3.44).  Thus, although the 
biochemical nature of the phospholipid may be one of the ultimate determinants of the 
binding specificity of a peptide to the LPS, the structural propensity of the peptides in 
the microenvironment of anionic phospholipids could strongly influence the structure 
and function of the molecule, which in turn determines its specificity for the lipids in 
the microenvironment. Thus, these results could contribute to the understanding of the 
mechanism of the interaction between Sushi peptides and LPS. Moreover, because S1 
and S3 peptides are derived from different LPS-binding domains of the Factor C 
molecule, it would appear that the Factor C molecule  harbors rather versatile modes 
of interaction with bacterial lipids (Nakamura et al., 1988), where the a-helical and 
ß-sheet structures of the Sushi domains may conceivably bind LPS and even 
co-operate to stabilize the Factor C protein , maintaining it as an extremely sensitive 
biosensor for Gram negative infection (Ariki et al., 2004; Ding and Ho, 2001; Muta et 
al., 1991).  In view of the dual preferences of the Sushi peptides for LPS and POPG 
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on the GNB membrane  (Figure 4.3) , we envisage that POPG could be applied as a 





Figure 4.3 Sushi peptides interact with anionic lipids. The positively charged amino acids 
at the N-termini of S1 and S3, contribute to electrostatic interaction with the diphosphoryl 
head groups of the LPS/POPG; the C-termini are more hydrophobic, which probably interacts 
with the hydrophobic acyl chains of the LPS/POPG, forming a stable molecular complex.  
Taken together, both the electrostatic (red line) and hydrophobic interactions (blue line) are 
important for the Sushi peptides to bind to bacterial lipids, which contribute to the specific 





Chapter 5   Conclusions and Future Perspectives 
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In or der to provide an in-depth understanding of the activity of Sushi peptides, the  
detailed molecular mechanism of the interaction between Sushi peptides and LPS was 
studied in this work.  Here, we investigated the binding, structure and function of the  
Sushi peptides using a series of methods.  One of our methods was fluorescence 
correlation spectroscopy (FCS), which is applied for the first time in such a study.   
This chapter concludes the main findings of the research work described in this thesis 
and presents the hypothetical models for the molecular mechanisms of action of the 
Sushi 1 and 3 peptides.  Some insights into future perspectives are also presented. 
 
5.1 Main findings 
This thesis demonstrates that Factor C efficiently inhibits the LPS-induced p38 
phosphorylation and cytokine production. This gave us reason to believe that the 
LPS-binding domains in the Factor C molecule could be examined for their anti-LPS 
activities with a view to developing them into LPS-antagonists. Towards this end, the 
Sushi peptides (S1 and S3) were investigated for their mechanisms of interaction with 
LPS.  Recombinant S3 peptide of 36 amino acids length (including D, P residues at 
its N- and C-terminii), was expressed and purified.  Although the recombinant 
peptide (rS3) was less active than the chemically synthesized counterpart, the initial 
observations made with the rS3 peptide suggest the feasibility of using the Sushi 
peptides for anti-LPS study and applications. 
Using chemically synthesized S1 and S3, we also found that both electrostatic  
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and hydrophobic forces contribute significantly to the interaction between the Sushi 
peptides and LPS.  The electrostatic interactions between the cationic amino acids on 
the peptides and the anionic headgroup on the LPS are deemed to be critical for 
binding, explaining why the increase in the net positive charge of the peptides could 
enhance their binding to anionic lipids.  This is in agreement with the previous report 
that mutations at the N-terminus that introduce two extra lysine residues into Sushi 
peptides resulted in an increase in LPS-neutralizing activity (Tan 2000 et al.).    Our 
data revealed that the microenvironments of the Sushi peptides were transformed 
from a hydrophilic to a more hydrophobic state, thus engaging the hydrophobic region 
of the peptide into an interactive bond with the acyl chains of LPS.  Owing to the 
simultaneous electrostatic and hydrophobic interactions, the binding of Sushi peptides 
with LPS should be highly salt-tolerant and thus suggests the robustness of the 
peptides for future research and development.  
 This work also shows that the interaction and activity of Sushi peptides are 
related to the structures of the peptides.  The secondary structures of the peptides 
confer stability to the S1 and S3 peptides for their prolonged and persistent interaction 
with LPS aggregates prior to the disruption of these aggregates (Table 6).  S1 peptide 
is random in an aqueous environment and exhibits a characteristic a -helical structure  
in the presence of an anionic phospholipids.  In contrast, S3 remained unchanged in 
buffer, but the content of a -helix increased slightly in the presence of POPG, 
producing a mixture of a -helix and ß -strand structures.  The reason for this 
difference lies in the secondary structures of S1 and S3 peptides, where S3 is probably 
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stabilized by the intermolecular disulfide bond.  Thus, S1 and S3 peptide s disrupt the 
LPS aggregates via subtly different mechanisms. Given that S1 and S3 peptides are 
derived from different LPS-binding domains of the Factor C molecule, it appears that 
Factor C harbors rather versatile modes of interaction with LPS, a proposal made by 
Tan et al. (2000b) , where the a-helical and ß-sheet structures of the Sushi domains 
may conceivably bind LPS and even co-operate to strengthen Factor C protein as an 
extremely sensitive biosensor to Gram negative infection (Ariki et al., 2004; Ding and 
Ho, 2001; Muta and Iwanaga, 1996).  
Furthermore, we have reported the use of fluorescence correlation spectroscopy 
(FCS) as a novel solution-based approach to monitor the molecular interaction 
between the Sushi peptides and LPS.  Compared with the traditional approaches, 
FCS is a faster and more sensitive method (Table 7).  Either fluorescence labeled 
peptides or labeled LPS were used as reporter molecules to monitor the interaction.   
Two different FCS detection systems were set up.  Compared with several other 
surface-based biochemical approaches, we demonstrated that the FCS is a more rapid 
and more convenient method to monitor the interaction between LPS and peptides in 
solution.   
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Table 6 The comparison of the characteristics of S1 and S3 peptide  
 S1 S3 
Source Sushi 1 domain of Factor C Sushi 3 domain of Factor C  
Molecular weight ~3.8 kD ~3.8 kD  
Cysteines 3 1 
Monomer or Dimer monomer dimer 
Structure in buffer random coil The mixture of a-helix and 
b-sheet 
Structure in anionic 
phospholipids 
a-helix The mixture of a-helix and 
b-sheet 
The effect on LPS 




Table 7 The comparison of different approaches in LPS binding peptide research 
 ELISA SPR FCS rFC assay 
Requirement of antibody 
or substrate  
antibody No No substrate  
Sample concentration nM - mM nM - mM nM nM - mM 






Label molecules No No Yes No 
System Plate reader Biacore Confocal 
microscope  
Plate reader 




5.2 The hypothetical models for the interaction of Sushi peptides with LPS 
Here, we propose hypothetical models for the specific interactions between Sushi 
peptides, S1 & S3 with LPS (Figure 5.1 A & B).  Because of the negative charge on 
the headgroup of LPS and the positive charge attributable to the Lys and Arg residues 
on S1, S3 peptide, specific charge -charge interaction occurs between S1 and S3 and 
LPS aggregates during which the peptide is drawn close to the surface of the LPS 
layer.   
Figure 5.1A shows S1 peptide model: Initially, the structure of S1 is random in 
solution. Whilst being inserted into the microenvironment of the anionic LPS, S1 
changes conformation from  random to a-helix.  Thus, their positively charged amino 
acids face the negatively charged headgroups of the LPS, and their hydrophobic 
amino acids, such as Trp, insert in to the lipid acyl chains. 
S3 interacts preferentially with LPS molecules in a different manner (Figure 5.1B): 
initially, dimerisation of S3 peptide occurs through an intermolecular disulfide bond; 
subsequently, at the initial low ratio of S3:LPS, binding of the S3 dimer to LPS 
aggregates occurs via electrostatic and hydrophobic interactions; then as more S3 
dimer accumulates at the local environment of the LPS aggregates, and the insertion 
of the peptide into the LPS layer initiates its disruption.  When a threshold 
concentration of S3 dimer peptide is reached, perturbation of the LPS aggregates is 
maximal, culminating in pore formation and complete disruption of the LPS layer.  
Because the S3 dimer is a sym metrically structured peptide , we propose that in the 
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interaction process, one S3 dimer binds two LPS molecules to form a complex 
constituting a trio of LPS:S3 dimer:LPS. 
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         (A) The model of S1 interact ion with LPS. 
 




Figure  5.1 The model of interact ion between Sushi peptides, S1 and S3, with LPS.  
(A) A hypothetical model for S1 interaction with LPS. (1) S1 peptide specifically binds LPS 
via electrostatic interactions. Subsequently, S1 forms an ?a-helical structure to insert into the 
LPS layer. S1 and LPS form a complex by electrostatic interaction of the positively charged 
amino acid residues and the negatively charged bisphosphate headgroups of the LPS and 
hydrophobic interactions between the hydrophobic region of S1 and the acyl chains of LPS 
(insert). (3) When a threshold concentration of S1 peptide is reached, LPS aggregates is 
perturbed.  
(B) A hypothetical model for S3 interaction with LPS. (1) Dimerisation of S3 peptide occurs 
through an intermolecular disulfide bond. (2) At the initial low ratio of S3:LPS, binding of S3 
dimer to LPS occurs. (3) Following the hydrophobic insertion of the peptide into the LPS 
layer results in pore formation, which is maintained by multiple points of chemical interaction, 
between one S3 dimer  and two LPS molecules, forming a complex of LPS:S3 dimer :LPS 
(insert).  This initiates the dis ruption of LPS micelles.  When a threshold concentration of 
S3 dimer peptide is reached, the perturbation of LPS can be found (Adapted from Hancock 
and Chapple, 1999 with some modifications). (Hancock and Chapple, 1999)  
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5.3  Future perspectives 
This work has provided a platform of useful information and new hypotheses on 
how LPS-antagonistic peptides may function.  The data in this thesis have opened 
new avenues to be explored: 
 (1) Since the electrostatic and hydrophobic forces determine the interaction 
between Sushi peptides and LPS, it would be imperative to examine the contribution 
of the positive ly charged amino acids and hydrophobic amino acids to the interaction  
with LPS.  Thus, future work may attempt to introduce extra hydrophobic or 
positively charged amino acids into the Sushi peptides to investigate how the binding 
affinity may be altered.   This would entail parallel investigation of the selectivity of 
the new peptides for bacterial membrane lipids and also, their level of toxicity to the 
mammalian host cell.  
(2) Sushi peptides (S1 and S3) demonstrate different secondary structures.  Thus, 
novel hybrid Sushi peptides could be designed by linking the S1 and S3 directly or by 
disulfide bond. Also, an additional amino acid sequence could be added to flank S1 
and S3 peptides to form the hybrid Sushi peptides.  The chemically synthesized 
hybrid of S1-S3 peptide could be analyzed to determine any potential additive or 
cooperative effects compared with the native Sushi peptides.   
(3) Sushi peptides bind LPS with high affinity; however the tertiary structures of 
Sushi peptides are not resolved.  In this research, earlier attempts have been made to 
solve the tertiary structure of the Sushi peptides. However, the 1D 1H NMR spectrum 
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peaks were rather broad and the resolution was poor. Thus, the detailed solution 
structures of the complexes remained unresolved to date . In order to design more 
powerful peptide drugs in the future, crystallography may be used to reveal the 
tertiary structure of peptides. 
(4) Even though Sushi peptides are potential LPS-antagonists, various 
considerations should be noted that in addition to its structure, the maintenance of 
peptide solubility is a critical parameter in the design of an improved LPS-binding 
and neutralizing-pept ide.  Furthermore, the peptide mimic should be nontoxic to 
humans and resistant to degradation by proteases in vivo , especially prior to reaching 
its site of antimicrobial action. Thus, a prolonged half -life of the peptide would be 
desirable  by introducing the modification into the amino acids to protect the peptides 
from degradation. For example, since trypsin cleaves C-terminus to arginine and 
lysine residues, the modification or mutation of these arginine and lysine residues 
may help to block the digestion by trypsin. 
 (5) Our results demonstrate that Sushi peptides bind to LPS with high affinity. 
However, the source of LPS comes from E. coli and P. aeruginosa . Thus there is a 
need to investigate whether Sushi peptides can interact with LPS from the other  
strains of GNBs in order to compare their affinities.  This will help to ascertain the  
potential application of the peptide as general LPS-neutralizing drugs.  
     (6) In these cellular assays, anti-endotoxin potency of Factor C derived protein 
or Sushi peptides were attenuated in the presence of serum (Tan et al. 2000a). This 
could be due to the interaction of the serum factors with peptides, which effectively 
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reduces their availability for binding to endotoxin. Thus, a detailed study on the 
LPS-neutralizing effect of the S1 or S3 peptide in serum-containing medium would be 
required to prior to using these peptides in vivo . 
 (7) Since POPG exists on the bacterial membrane, the preferential interaction 
with unsaturated phospholipid, POPG, may be applied as a means by which Sushi 
peptides and other antimicrobial peptides can gain easier insertional access through a 
more fluidic bacterial membrane environment, to enhance and stabilize the 
peptide-LPS complex.  In view of the dual preference of the Sushi peptides for LPS 
and POPG on the GNB membrane, it may be envisaged that POPG could be applied 
as a potential adjuvant to improve the anti-LPS activity of the Sushi peptides. 
 (8) In this study we have reported for the first time the use of FCS to monitor the 
binding of Sushi peptides with LPS in vitro . The FCS system here was simple, with 
only Sushi peptides and LPS as the components. Since LPS and POPG are co-existent 
on bacterial membrane and Sushi peptides are found to kill GNB (Yau et al., 2001) , it 
would be interesting to use live bacteria to study the interaction of Sushi peptides with 
LPS and other bacterial membrane lipids by using realtime FCS instead of the 
endpoint system.  Therefore, it would be more useful if FCS application can be 
extended to detect the binding of LPS in real life microbes and infected cell culture 
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